text:
Tag Archives: patents
Who's running the life science companies' public relations campaign in British Columbia (Vancouver, Canada)?
I started writing this in the aftermath of the 2021 Canadian federal budget when most of the action (so far) occurred but if you keep going to the end of this post you'll find updates for Precision Nanosystems and AcCellera and a few extra bits. Also, you may want to check out my August 20, 2021 posting (Getting erased from the mRNA/COVID-19 story) about Ian MacLachlan and some of the 'rough and tumble' of the biotechnology scene in BC/Canada. Now, onto my analysis of the life sciences public relations campaign in British Columbia.
Gordon Hoekstra's May 7, 2021 article (also in print on May 8, 2021) about the British Columbia (mostly in Vancouver) biotechnology scene in the Vancouver Sun is the starting point for this story.
His entry (whether the reporter realizes it or not) into a communications (or public relations) campaign spanning federal, provincial, and municipal jurisdictions is well written and quite informative. While it's tempting to attribute the whole thing to a single evil genius or mastermind in answer to the question posed in the head, the 'campaign' is likely a targeted effort by one or more groups and individuals enhanced with a little luck.
Federal and provincial money for life sciences and technology
The Business Council of British Columbia's April 22, 2021 Federal & B.C. Budgets 2021 Analysis (PDF), notes this in its Highlights section,
•Another priority reflected in both budgets is boosting innovation and accelerating the growth of technology-producing companies. The federal budget [April 19, 2021] is spending billions more to support the life sciences and bio-manufacturing industry, clean technologies, the development of electric vehicles, the aerospace sector, quantum computing, AI, genomics, and digital technologies, among others.
•B.C.'s budget [April 20, 2021] also provides funding to spur innovation, support the technology sector and grow locally-based companies. In this area the main item is the new InBC Investment Corporation [emphasis mine], first announced last summer. Endowed with $500 million financed via an agency loan, the Corporation will establish a fund to invest in growing and "anchoring" high-growth [emphasis mine] B.C. businesses.
Their in-depth analysis does not provide more detail about the life sciences investments in the 2021 Canadian federal budget or the 2021 BC provincial budget.
My May 4, 2021 posting details many of the Canadian federal investments in life sciences and other technology areas of interest. The 2021 BC budget announcement is so vague, it didn't merit much more than this mention until now.
InBC Investment Corporation (BC's contribution)
InBC Investment Corporation was set up on or about April 27, 2021 as three news 'references' (brief summaries with a link) suggest: InBC Investment Corp. Act, InBC Announcement, $500-million investment fund paves way for StrongerBC.
While the corporation does not have a specific mandate to fund the biotechnology sector, given the current enthusiasm, it's easy to believe they might be more inclined to fund them than not, regardless of any expertise they or may not have specifically in that field.
Of most interest to me was InBC's Board of Directors, which I tracked down to a BC Ministry of Jobs, Economic Recovery and Innovation May 6, 2021 news release,
InBC Investment Corp. now has a full board of directors with backgrounds in finance, economics, impact investing and business to provide strategic guidance and accountability for the new Crown corporation.
InBC will support startups [emphasis mine], help promising companies scale up and work with a "triple bottom line" mandate that considers people, the planet and profits, to position British Columbia as a front-runner in the post-pandemic economy.
Christine Bergeron, president and chief executive officer of Vancity, will serve as the new board chair of InBC Investment Corp. The nine-member board of directors is made up of both public and private sector members who are responsible for oversight of the corporation, including its mission, policies and goals.
The InBC board members were selected through a comprehensive process, guided by the principles of the Crown Agencies and Board Resourcing Office. Candidates with a variety of relevant backgrounds were considered to form a strong board consisting of seven women and two men. The members appointed represent diversity as well as appropriate areas of expertise.
The following people were selected as members on the board of directors:
Christine Bergeron, president and CEO, Vancity
Kevin Campbell, managing director of investment banking, board of directors, Haywood Securities
Ingrid Leong, VP finance for JH Investments and chief investment officer, Houssian Foundation
Glen Lougheed, serial tech entrepreneur and angel investor
Suzanne Trottier, vice-president of Indigenous trust services, First Nations Bank Trust
Carole James, former minister of finance and deputy premier, Government of British Columbia
Iglika Ivanova, senior economist, public interest researcher, BC Office of the Canadian Centre for Policy Alternatives
Bobbi Plecas, deputy minister, B.C.'s Ministry of Jobs, Economic Recovery and Innovation
Heather Wood, deputy minister, B.C.'s Ministry of Finance
Legislation to provide the governance framework for InBC was introduced by the legislative assembly on April 27, 2021.
Board experience at growing a startup?
This group of people doesn't seem to have a shred of experience with startups. Glen Lougheed's "serial tech entrepreneur and angel investor" description means nothing to me and the description he provides in his LinkedIn profile doesn't clear up matters,
I am a product and business development professional with an entrepreneurial attitude and strong technical skills. I have been building companies both mine and others since I was a teenager.
Having looked up the two companies for which he is currently acting as Chief Executive Officer, Lougheed's interest appears to be focused on the use of 'big data' in marketing and communications campaigns.
Perhaps startup experience isn't necessary since the board has been appointed to do this (from the BC Ministry of Jobs, Economic Recovery and Innovation May 6, 2021 news release; click on the Backgrounder),
Responsibilities of the InBC Investment Corp. board of directors
The board of directors will be responsible for oversight of the management of the affairs of the corporation. This includes:
selecting and approving the chief executive officer and chief innovation officer and monitoring performance and accountabilities;
reviewing and approving annual corporate financial statements;
oversight of policies that relate to InBC's mandate and holding the executive to account for its accountabilities with respect to InBC's mandate;
oversight of InBC's operations; and
selection and appointment of InBC's auditor.
So, we have two government civil servants, Wood (Deputy Minister of B.C.'s Ministry of Finance) and Plecas (Deputy Minister of B.C.'s Ministry of Jobs, Economic Recovery and Innovation), and James, a BC Minister of Finance, who left the job several months ago. Then we have Lougheed, recently resigned (May 2021) as special advisor on innovation and technology to the BC Minister of Jobs, Economic Recovery and Innovation.
It would seem almost half of this new board is or has been affiliated with the government and, likely, know each other.
I expect there are more relationships to be found but my interest is in the overall picture as it pertains to the biotechnology scene. This board (except possibly for Lougheed) does not seem to have any experience in the biotechnology sector or growing any sort of startup business in any technology field.
Presumably, the new chief executive officer (CEO) and new chief innovation officer (CIO) will have some of the necessary experience. Still, biotechnology isn't the same as digital technology, an area where the BC technology community is quite strong. (The Canadian federal government's Digital Technology Supercluster is headquartered in BC.)
I imagine the politics around who gets hired as CEO and as CIO will be quite interesting.
See the 'Updates and extras' at the end of this posting for more mention of this 'secretive' government corporation.
The BC biotech gorillas
AbCellera was BC's biggest biotech story in 2020/21 (see my Avo Media, Science Telephone, and a Canadian COVID-19 billionaire scientist post from December 30, 2020 for more. Do check out the subsection titled "Avo Media …" for a look at an unexpectedly interlaced relationship). Note: The AbCellera COVID-19 treatment is not a vaccine or a vaccine delivery system.
It was a bit surprising that Acuitas Therapeutics didn't get more attention although Hoekstra seems to have addressed that shortcoming in his May 7, 2021 article by using Thomas Madden and Acuitas as the hook for the story,
By early 2020, concern was mounting about a new, deadly coronavirus first detected in Wuhan, China.
The World Health Organization had declared the coronavirus outbreak a global health emergency just days before. There had been more than 400 deaths and more than 20,000 cases, most of those in China.
But the virus was spreading around the world. Deaths had occurred in Hong Kong and the Philippines, and the virus had been detected in the U.S. and Canada.
By early January of 2020, scientists in China had already sequenced the virus's genome and made it public, allowing scientists to begin the research for a vaccine.
Scientists expected that could take years.
But, as a second case was confirmed in B.C. in early February, Thomas Madden, a world-renowned expert in nanotechnology who heads Vancouver-based biotech company Acuitas Therapeutics, flew to Germany. [emphases mine]
Acuitas was in the business of creating lipid nanoparticles, microscopic biological vehicles that could deliver drugs [emphasis mine] — for example, to specifically target cancers in the body.
Scientists are already beginning to say it's likely that a booster vaccine will be needed [emphasis mine] next year to deal with the virus variants.
Madden, the head of Acuitas, says it makes absolute sense to use the new biotechnology, for example, the use of messenger RNA vaccines, to prepare and fight future pandemics.
Says Madden [emphasis mine]: "The technology in terms of what it's able to do is absolutely phenomenal. It's just taken us 40 years to get here."
So, Hoekstra reminds us of the international nature and urgency of the crisis, then, introduces Acuitas as a vital and local player in solutions deployed internationally, and, finally, brings us back to Acuitas after providing an overview of the BC biotech scene and the federal and provincial government's latest moves,
AbCellera Biologics is more of a supporting player, along with a number of other companies, in Hoekstra's story,
Sandwiched in the middle, you'll find what I think is the point of the story,
LifeSciences BC and the provincial government's commitments
From Hoekstra's May 7, 2021 article,
The importance of the biotech sector in providing protection against pandemics has caught the attention of the federal and B.C. governments. It has also been noticed by the private markets.
In its budget [April 19, 2021] earlier this month [sic], the federal government promised more than $2 billion in the next seven years to support "promising" life sciences and bio-manufacturing firms, research, training, education and vaccine candidates.
Some companies, including Precision NanoSystems, have already got federal funding. The Vancouver company received $18.2 million last year to help develop its self-replicating mRNA vaccine and another $25 million in early 2021 to assist building a $50-million facility to produce the vaccine.
Last fall, Symvivo received $2.8 million from the National Research Council to help develop its oral COVID-19 vaccine.
AbCellera has also received a pledge of $175.6 million to help build an accredited manufacturing facility in Vancouver [emphasis mine] to produce antibody treatments.
AbCellera expects to double its 230-person workforce over the next two years as it expands its Vancouver campus.
When AbCellera became a publicly traded company late last year, it raised more than $500 million and had a recent market capitalization, the value of its stock, of about $8.5 billion.
When the B.C. government delivered its throne speech recently, the contribution of the province's life sciences sector in the fight against the COVID-19 pandemic was highlighted, with Precision NanoSystems, AbCellera and StarFish Medical getting mentions. "Their work will not only help bring us out of the pandemic, it will position our province for success in the years ahead," said B.C.'s Lt. Gov. Jane Austen in delivering the throne speech.
When the budget was released the following week [April 20, 2021], B.C. Finance Minister Selina Robinson said a new three-year, $500-million strategic investment fund would help support and scale up tech firms.
Despite their successes, B.C. biotech firms have faced challenges.
SaNOtize had to go to the U.K. to get support for clinical trials and AbCellera has been disappointed that despite Health Canada emergency approval of its COVID-19 treatment, provinces have been reluctant to use Bamlanivimab.
Hansen, AbCellera's CEO and a former University of B.C. professor with a PhD in applied physics and biotechnology, said he believes that biotech is the most important frontier of technology.
In the past, while great science was launched from B.C.'s universities, not as great a job was done on turning that science into innovation, jobs [emphasis mine] and the capacity to bring new products to market, possibly because of a lack of entrepreneurship and polices to make it more attractive to companies to grow and thrive here and move here, notes Hansen.
Hurlburt [Wendy Hurlburt], the LifeSciences B.C. CEO, says that policies, including tax structure and patenting [emphasis mine], that encourages innovation companies are needed to support the biotech sector.
But, adds Hansen: "Here in Vancouver, I feel like we're turning the corner. There's probably never been a time when Vancouver's biotech sector [emphasis mine] was stronger. And the future looks very good."
Not only is the province involved but so is the City of Vancouver (more about that in a bit).
It's not all about the cash
Hoekstra's May 7, 2021 article helped answer a question I had in the title of another posting, January 22, 2021: Why is Precision Nanosystems Inc. in the local (Vancouver, Canada) newspaper? (See the 'Updates and extras' at the end of this posting for more to the answer.)
This campaign has been building for a while. In the "Is it magic or how does the federal budget get developed? subsection of my May 4, 2021 posting on the 2021 Canadian federal budget I speculated a little bit,
I believe most of the priorities are set by power players behind the scenes. We glimpsed some of the dynamics courtesy of the WE Charity scandal 2020/21 and the SNC-Lavalin scandal in 2019.
Access to special meetings and encounters are not likely to be given to any member of the 'great unwashed' but we do get to see the briefs that are submitted in anticipation of a new budget. These briefs and meetings with witnesses are available on the Parliament of Canada website (Standing Committee on Finance (FINA) webpage for pre-budget consultations.
AbCellera submitted a brief dated August 7, 2020 (PDF) detailing how they would like to see the Income Tax Act amended. It's not always about getting cash, although that's very important. In this brief, the company wants "… improved access to the enhanced Scientific Research & Experimental Development tax credit."
There are many aspects to these campaigns including the federal Income Tax Act and, in this case, municipal involvement.
Vancouver (city government) and the biotech sector
About five weeks prior to the 2021 Canadian federal budget and BC provincial budget announcements, there was some news from the City of Vancouver (from a March 10, 2021 article by Kenneth Chan for dailyhive.com), Note: Links have been removed,
Major expansion plans are abound for AbCellera over the next few years to the extent that the Vancouver-based biotechnology company is now looking to build a massive purpose-built office and medical laboratory campus in Mount Pleasant (Vancouver neighbourhood).
It would be a redevelopment of the entire city block …
… earlier today, Vancouver City Council unanimously approved a rezoning enquiry allowing city staff to work with the proponent and accept a formal application for review.
This special additional pre-application step is required due to the temporary ban [emphasis mine] on most types of rezonings within the Broadway Plan's planning area, until the plan is finalized at the end of 2021.
But city staff are willing to make this a rare exception due to the economic opportunity [emphasis mine] presented by the proposal and the healthcare-related aspects.
"The reasons for advancing this quickly are they are rapidly growing and would like to stay in Vancouver, and we would like them to… We're very glad to have this company in Vancouver and want to provide them with a permanent home, but in order to scale up, the timeframe to produce their therapy [for viruses] is really time sensitive," Gil Kelley, the chief urban planner of the City of Vancouver, told city council during today's [March 10, 2021] meeting.
Roughly 10 days after the 2021 budgets are announced, there's this from Kenneth Chan's April 29,2021 article on dailyhive.com,
Plans for AbCellera Biologics' major footprint expansion in Vancouver's Mount Pleasant Industrial Area are moving forward quickly.
Based on the application submitted this week, the Vancouver-based biotechnology company is proposing to redevelop 110 West 4th Avenue …
It will be designated as the rapidly growing company's global headquarters.
… city staff are providing AbCellera with the highly rare, expedited stream of combining the rezoning and development application processes into one.
By the middle of this decade, AbCellera will have four locations in the area, including its current 21,000 sq ft office at 2215 Yukon Street and a new 44,000 sq ft office nearing completion at 2131 Manitoba Street, just south of its future main hub.
"We're building state-of-the-art facilities in Vancouver to accelerate the development of new antibody therapies with biotech and pharma partners from around the world," said Carl Hansen, CEO and president of AbCellera, in a statement.
AbCellera has gained significant international attention over the past year after it co-developed the first authorized COVID-19 antibody therapy for emergency use in high-risk patients in Canada and the United States.
In late 2020, the company closed a successful initial public offering, bringing in $556 million after selling nearly 28 million shares, far exceeding its original goal of raising $250 million. It was the largest-ever IPO [initial public offering] by a Canadian biotech company.
"We see this new site as a creative hub for engineers, software developers, data scientists, biologists and bioinformaticians to collaborate, innovate, and push the frontiers of technology." [said Veronique Lecault, the COO of AbCellera]
Additionally, AbCellera is also planning to build a clinical-grade, antibody manufacturing facility in Metro Vancouver, funded in part by the $176-million investment it received from the federal government in Spring 2020 [see May 3, 2020 AbCellera news release].
Not cash but AbCellera did get an expedited process for rezoning and I imagine there will be more special treatment as this progresses. (See the 'Updates and extras' at the end of this posting for news about the expedited process.)
It's likely there are other companies in the BC's life science sector that are eyeing this development with great interest and high hopes for themselves.
COVID-19 seems to have galvanized interest and support almost everywhere in the world for life sciences.
I don't believe that anyone in the life sciences planned for or rejoiced at news of this pandemic. However, the Canadian biotech sector has been working for decades to establish itself as an important economic resource. and, sadly, COVID-19 has been a timely development.
All those years of lobbying, also known as, government relations, marketing, investor relations, public relations and more served as preparation for what looks like a concerted effort and it has paid off in BC at the federal level, provincial level, and municipal level (at least one).
The campaigns continue. Here's Wendy Hurlburt, president and CEO of LifeSciences BC in a May 14, 2021 Conversations That Matter Vancouver Sun podcast with Stuart McNish. Note: Hurlburt makes an odd comment at about the 7 min. 30 secs. mark regarding insulin and patents.
Her dismay over lost opportunities regarding the insulin patent is right in line with Canada's current patent mania. See my May 13, 2021 posting, Not a pretty picture: Canada and a patent rights waiver for COVID-19 vaccines. As far as I'm aware, Canada's stance has not changed. Interestingly, Hoekstra's article doesn't mention COVID-19 patent waivers.
By contrast, here's what Frederick Banting (one of the discoverers) had to say about his patent, (from the Banting House Insulin Patents webpage),
About the sale of the patent of insulin for $1 Banting reportedly said, "Insulin belongs to the world, not to me."
… On January 23rd, 1923 Banting, [Charles] Best, and [James] Collip were awarded the American patents for insulin which they sold to the University of Toronto for $1.00 each.
Hurlburt goes on to express dismay over taxes and notes that some companies may leave for other jurisdictions, which means we will lose 'innovation'. This is a very common ploy coming from any of the technology sectors and can be dated back at least 30 years.
Unmentioned is the dream/business model that so many Canadian tech entrepreneurs have: grow the company, sell it for a lot of money, and retire, preferably before the age of 40.
Getting back to my point, the current situation is not attributable to one individual or to one company's efforts or to one life science nonprofit or to one federal Network Centre for Excellence (NanoMedicines Innovation Network [NMIN] located at the University of British Columbia).
Note: I have more about the NMIN and Acuitas Therapeutics in a November 12, 2021 posting and there's more about NMIN's 7th annual conference and a very high profile guest in a September 11, 2020 posting.
Strategy at the federal, provincial, and local governments, with an eye to the international scene, has been augmented by luck and opportunism.
Updates and extras
Where updates are concerned I have one for Precision Nanosystems and one for AbCellera. I have extras with regard to Moderna and Canada and, BC's special fund, inBC Investment Corporation. For anyone who's curious about Banting and the high cost of insulin, I have a couple of links to further reading.
Precision Nanosystems
From an August 11, 2021 article by Kenneth Chan (Note: Links have been removed),
A homegrown pharmaceutical company has announced plans to significantly scale its operations with the opening of a new production facility in Vancouver's False Creek Flats.
The new Evolution Block building will contain PNI's new global headquarters and a new genetic medicine Good Manufacturing Practice (GMP) biomanufacturing centre, which would allow the company to expand its capabilities to include the clinical manufacturing of RNA vaccines and therapeutics.
Federal funding totalling $25.1 million for PNI was first announced in February 2021 towards covering part of the development costs of such a facility, as part of the federal government's new strategy to better ensure Canada has the domestic capacity to secure its own COVID-19 vaccines and prepare the country for future pandemics. It is estimated the vaccine production capacity of the new facility will be 240 million doses annually.
PNI's location in the False Creek Flats is strategic, given the close proximity to the new St. Paul's Hospital campus and the growing concentration of tech and healthcare-based industrial businesses.
AbCellera
From a June 22, 2021 article by Kenneth Chan (Note: Links have been removed),
The rapidly growing Vancouver-based biotechnology company announced this morning their 130,000 sq ft Good Manufacturing Practices (GMP) facility will be located on a two-acre site at the 900 block of Evans Avenue, replacing the Urban Beach volleyball courts just next to the City of Vancouver's Evans maintenance centre and the Regional Recycling Vancouver Bottle Depot.
GMP is partially funded by the $175 million in federal funding received by the company last year to support research into coronavirus treatment.
GMP adds to AbCellera's major plans to build a new headquarters in close proximity at 110-150 West 4th Avenue in the Mount Pleasant Industrial Area — a city block-sized campus with a total of 380,000 sq ft of laboratory and office space for research and corporate uses.
Both campus buildings are being reviewed under the City of Vancouver's rare streamlined, expedited process [emphasis mine] of combining the rezoning and development permit applications. AbCellera formally announced its campus plans in April 2021.
AbCellera gained significant international attention last year when it developed the world's first monoclonal antibody therapy for COVID-19 to be authorized for emergency use in high-risk patients in Canada and the United States. According to the company, over 400,000 doses of its bamlanivimab drug have been administered around the world, and it is estimated to have kept more than 22,000 people out of hospital — saving at least 11,000 lives.
In late 2020, the company closed a successful initial public offering, bringing in $556 million after selling nearly 28 million shares, far exceeding its original goal of raising $250 million. It was the largest-ever IPO by a Canadian biotech company.
Moderna and Canada
It seems like yesterday that Derek Rossi (co-founder of Moderna) was talking about Canada's need for a biotechnology hub. (see this June 17, 2021 article by Barbara Shecter for the Financial Post). Interestingly, there's been an announcement of a memorandum of understanding (these things are announced all the time and don't necessarily result in anything) between Moderna and the government of Canada according to an August 10, 2021 item on the Canadian Broadcasting Corporation (CBC) news website,
Massachusetts-based drug maker Moderna will build an mRNA vaccine manufacturing plant in Canada within the next two years, CEO Stephane Bancel said Tuesday [August 10, 2021; Note the timing, the writ for the next federal election was dropped on August 15, 2021].
The company has signed a memorandum of understanding with the federal government that will result in Canada becoming the home of Moderna's first foreign operation. It's not clear yet how much money Canada has offered to Moderna [emphasis mine] for the project.
Canada, whose life sciences industry has been decimated over the last three decades, wants in on the action. Prime Minister Justin Trudeau has promised to rebuild the industry, and the recent budget included a $2.2 billion, seven-year investment to grow the life science and biotech sectors.
Almost half of that targets companies that want to expand or set up vaccine and drug production in Canada. None of the COVID-19 vaccines to date have been made in Canada, leaving the country entirely reliant on imports to fill vaccine orders. As a result, Canada was slower out of the gate on immunizations than some of its counterparts with domestic production, and likely had to pay more per dose for some vaccines as well.
The location of the new facility hasn't been finalized, but Bancel said the availability of an educated workforce will be the main deciding factor. He said the design is done and they'll need to start hiring very soon so training can begin.
it's not exactly a hub but who knows what the future will bring? I imagine there's going to be some serious wrangling behind the scenes as the provinces battle to be the location for the facility. Note that Innovation Minister François-Philippe Champagne who made the announcement with Bancel in Montréal represents a federal riding in Québec. (BTW, Bancel is from France and seems to have spent much of his adult life in the US.) Of course anything can happen and I'm sure the BC contingent will make themselves felt but it would seem that Quebec is the front runner for now, assuming this memorandum of understanding leads to a facility. Given that we are in the midst of a federal election, it seems more probable than it might otherwise.
inBC Investment Corporation
Bob Mackin's August 13, 2021 article for theBreaker.news sheds some light on how that corporation was formed so very quickly and more,
The B.C. NDP government rejigged the B.C. Immigrant Investor Fund last year, but refused to release the business case when it was rebranded as inBC Investment Corp. in late April [2021].
theBreaker.news requested the business case for the $500 million fund, which is overseen by a board of NDP patronage appointees, on May 6 [2021].
The 123-page document below is heavily censored — meaning the NDP cabinet is refusing to tell British Columbians the projected operating costs (including board expenses, salary and benefits, office space, operating and administration), full-time equivalents, and cash flows for the newest Crown corporation. inBC bills itself as a triple-bottom line organization, meaning it intends to invest on the basis of social, environmental and economic values.
When its enabling legislation was tabled, the NDP took steps to exempt inBC from the freedom of information law.
Thank you, Mr. Mackin.
More on Banting, insulin and patents
Caitlyn McClure's 2016 article (Insulin's Inventor Sold the Patent for $1. Then Drug Companies Got Hold of It.) for other98.com is a brief and pithy explanation for why insulin costs so much. Alanna Mitchell's August 13, 2019 article for Maclean's magazine investigates 'insulin tourism' and offers more detail as to how this situation has come about.
One last reminder, my August 20, 2021 posting (Getting erased from the mRNA/COVID-19 story) about Ian MacLachlan provides insight into how competitive and rough the bitotechnology scene can be here in BC/Canada.
This entry was posted in business, intellectual property, marketing, medicine, nanotechnology, public perceptions, public relations, science policy, Vancouver and tagged (Canada) Digital Technology Supercluster, 2021 BC provincial budget, 2021 Canadian federal budget, AbCellera, Acuitas Therapeutics, Alanna Mitchell, Avo Media Science Telephone and a Canadian COVID-19 billionaire scientist, bamlanivimab, Barbara Shecter, BC Ministry of Finance, BC Ministry of Jobs Economic Recovery and Innovation, Bob Mackin, Bobbi Plecas, Business Council of British Columbia (BCBC), Caitlyn McClure, Canadian Centre for Policy Alternatives (CCPA), Carl Hansen, Carole James, Charles Best, Christine Bergeron, Conversations That Matter, COVID-19, Derek Rossi, First Nations Bank Trust, François-Philippe Champagne, Frederick Banting, Gil Kelley, Glen Lougheed, Good Manufacturing Practices (GMP), Gordon Hoekstra, Haywood Securities, Heather Wood, Houssian Foundation, Iglika Ivanova, InBC Investment Corporation (inBC), Ingrid Leong, insulin, Insulin's Inventor Sold the Patent for $1. Then Drug Companies Got Hold of It., James Collip, Kenneth Chan, Kevin Campbell, LifeSciences BC, lipid nanoparticles, Nanomedicines Innovation Network (NMIN), Not a pretty picture: Canada and a patent rights waiver for COVID-19 vaccines, patents, Precision NanoSystems, Ravi Kahlon, SaNOtize, Selina Robinson, StarFish Medical, Stephane Bancel, Stuart McNish, Suzanne Trottier, Symvivo, Thomas Madden, Vancity Savings Credit Union (Vancity), Veronique Lecault, Wendy Hurlburt on August 23, 2021 by Maryse de la Giroday.
A Café Scientifique Vancouver (Canada) October 29, 2019 talk ' Breeding stronger bees by shortcutting nature'
No, this talk does not not involve CRISPR (clustered regularly interspaced short palindormic repeats). This is about 'old fashioned' genetic breeding techniques with some 'fancy pants' words being thrown around. Also, somebody or other wants to patent this work on bees.
From a September 30, 2019 Café Scientifque announcement (received via email),
Our next café will happen on TUESDAY, OCTOBER 29TH at 7:30PM in the back room at YAGGER"S DOWNTOWN (433 W Pender). Our speaker for the evening will be DR. LEONARD FOSTER from the Department of Biochemistry and Molecular Biology at UBC [University of British Columbia].
BREEDING STRONGER BEES BY SHORTCUTTING NATURE
Dr. Leonard Foster's laboratory at UBC has been involved in a Canada-wide project aimed at bringing modern molecular technologies to bear on the selective breeding of honey bees that are better able to resist disease and stress. They use molecular fingerprinting and genomics to identify stronger bees, enabling their selective breeding. This brings up several controversial topics, including whether these bees are "natural", whether selectively bred bees could/should be patented and how far away direct genetic modification of honey bees will be. Dr. Foster will describe the state-of-the-art in bee genetics and where the future may lie here.
Dr. Leonard Foster is a Professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia. Dr. Foster comes from a family of beekeepers and got his introduction to academic bee research at Simon Fraser University while doing his Bachelor's
degree in biochemistry – at SFU [Simon Fraser University] he worked with Drs. Winston [Mark Winston] and Slessor [Keith Slessor] on honey bee pheromones, particularly the components of queen mandibular pheromone. He then did a Ph.D in Toronto a post-doctoral studies in Denmark before starting his current position in 2005. The first independent operating grant that Dr. Foster secured was to study how bee pathogens were able to manipulate the protein machinery within bee cells. Since that time he has led three very large-scale projects that have investigated some of the molecular mechanisms behind disease resistance in bees. This effort has recently moved into trying to apply this knowledge by using the information they have learned to guide selective breeding for hygienic behavior in honey bees. He is very active in extension and frequently engages the public on various aspects of honey bee biology. He currently lives in Richmond and keeps bees himself.
– Your Café Sci Vancouver Organizers
You can find out more about Leonard Foster and his work on this profile page on the University of British Columbia website, where I found this video,
One final comment, how are they going to patent a bee? For long time readers, it should be evident that I'm not a big fan of patents. They tend to impede research.
This entry was posted in intellectual property, public engagement, science communication, Vancouver and tagged bees, Breeding stronger bees by shortcutting nature, Cafe Scientifique, honey bees, hygienic behaviour, Keith Slessor, Leonard Foster, Mark Winston, patents, proteomics, Simon Fraser University (SFU), University of British Columbia (UBC) on October 29, 2019 by Maryse de la Giroday.
The Hedy Lamarr of international research: Canada's Third assessment of The State of Science and Technology and Industrial Research and Development in Canada (2 of 2)
Taking up from where I left off with my comments on Competing in a Global Innovation Economy: The Current State of R and D in Canada or as I prefer to call it the Third assessment of Canadas S&T (science and technology) and R&D (research and development). (Part 1 for anyone who missed it).
Is it possible to get past Hedy?
Interestingly (to me anyway), one of our R&D strengths, the visual and performing arts, features sectors where a preponderance of people are dedicated to creating culture in Canada and don't spend a lot of time trying to make money so they can retire before the age of 40 as so many of our start-up founders do. (Retiring before the age of 40 just reminded me of Hollywood actresses {Hedy] who found and still do find that work was/is hard to come by after that age. You may be able but I'm not sure I can get past Hedy.) Perhaps our business people (start-up founders) could take a leaf out of the visual and performing arts handbook? Or, not. There is another question.
Does it matter if we continue to be a 'branch plant' economy? Somebody once posed that question to me when I was grumbling that our start-ups never led to larger businesses and acted more like incubators (which could describe our R&D as well),. He noted that Canadians have a pretty good standard of living and we've been running things this way for over a century and it seems to work for us. Is it that bad? I didn't have an answer for him then and I don't have one now but I think it's a useful question to ask and no one on this (2018) expert panel or the previous expert panel (2013) seems to have asked.
I appreciate that the panel was constrained by the questions given by the government but given how they snuck in a few items that technically speaking were not part of their remit, I'm thinking they might have gone just a bit further. The problem with answering the questions as asked is that if you've got the wrong questions, your answers will be garbage (GIGO; garbage in, garbage out) or, as is said, where science is concerned, it's the quality of your questions.
On that note, I would have liked to know more about the survey of top-cited researchers. I think looking at the questions could have been quite illuminating and I would have liked some information on from where (geographically and area of specialization) they got most of their answers. In keeping with past practice (2012 assessment published in 2013), there is no additional information offered about the survey questions or results. Still, there was this (from the report released April 10, 2018; Note: There may be some difference between the formatting seen here and that seen in the document),
3.1.2 International Perceptions of Canadian Research
As with the 2012 S&T report, the CCA commissioned a survey of top-cited researchers' perceptions of Canada's research strength in their field or subfield relative to that of other countries (Section 1.3.2). Researchers were asked to identify the top five countries in their field and subfield of expertise: 36% of respondents (compared with 37% in the 2012 survey) from across all fields of research rated Canada in the top five countries in their field (Figure B.1 and Table B.1 in the appendix). Canada ranks fourth out of all countries, behind the United States, United Kingdom, and Germany, and ahead of France. This represents a change of about 1 percentage point from the overall results of the 2012 S&T survey. There was a 4 percentage point decrease in how often France is ranked among the top five countries; the ordering of the top five countries, however, remains the same.
When asked to rate Canada's research strength among other advanced countries in their field of expertise, 72% (4,005) of respondents rated Canadian research as "strong" (corresponding to a score of 5 or higher on a 7-point scale) compared with 68% in the 2012 S&T survey (Table 3.4). [pp. 40-41 Print; pp. 78-70 PDF]
Before I forget, there was mention of the international research scene,
Growth in research output, as estimated by number of publications, varies considerably for the 20 top countries. Brazil, China, India, Iran, and South Korea have had the most significant increases in publication output over the last 10 years. [emphases mine] In particular, the dramatic increase in China's output means that it is closing the gap with the United States. In 2014, China's output was 95% of that of the United States, compared with 26% in 2003. [emphasis mine]
Table 3.2 shows the Growth Index (GI), a measure of the rate at which the research output for a given country changed between 2003 and 2014, normalized by the world growth rate. If a country's growth in research output is higher than the world average, the GI score is greater than 1.0. For example, between 2003 and 2014, China's GI score was 1.50 (i.e., 50% greater than the world average) compared with 0.88 and 0.80 for Canada and the United States, respectively. Note that the dramatic increase in publication production of emerging economies such as China and India has had a negative impact on Canada's rank and GI score (see CCA, 2016).
As long as I've been blogging (10 years), the international research community (in particular the US) has been looking over its shoulder at China.
Patents and intellectual property
As an inventor, Hedy got more than one patent. Much has been made of the fact that despite an agreement, the US Navy did not pay her or her partner (George Antheil) for work that would lead to significant military use (apparently, it was instrumental in the Bay of Pigs incident, for those familiar with that bit of history), GPS, WiFi, Bluetooth, and more.
Some comments about patents. They are meant to encourage more innovation by ensuring that creators/inventors get paid for their efforts .This is true for a set time period and when it's over, other people get access and can innovate further. It's not intended to be a lifelong (or inheritable) source of income. The issue in Lamarr's case is that the navy developed the technology during the patent's term without telling either her or her partner so, of course, they didn't need to compensate them despite the original agreement. They really should have paid her and Antheil.
The current patent situation, particularly in the US, is vastly different from the original vision. These days patents are often used as weapons designed to halt innovation. One item that should be noted is that the Canadian federal budget indirectly addressed their misuse (from my March 16, 2018 posting),
Surprisingly, no one else seems to have mentioned a new (?) intellectual property strategy introduced in the document (from Chapter 2: Progress; scroll down about 80% of the way, Note: The formatting has been changed),
Budget 2018 proposes measures in support of a new Intellectual Property Strategy to help Canadian entrepreneurs better understand and protect intellectual property, and get better access to shared intellectual property.
What Is a Patent Collective?
A Patent Collective is a way for firms to share, generate, and license or purchase intellectual property. The collective approach is intended to help Canadian firms ensure a global "freedom to operate", mitigate the risk of infringing a patent, and aid in the defence of a patent infringement suit.
Budget 2018 proposes to invest $85.3 million over five years, starting in 2018–19, with $10 million per year ongoing, in support of the strategy. The Minister of Innovation, Science and Economic Development will bring forward the full details of the strategy in the coming months, including the following initiatives to increase the intellectual property literacy of Canadian entrepreneurs, and to reduce costs and create incentives for Canadian businesses to leverage their intellectual property:
To better enable firms to access and share intellectual property, the Government proposes to provide $30 million in 2019–20 to pilot a Patent Collective. This collective will work with Canada's entrepreneurs to pool patents, so that small and medium-sized firms have better access to the critical intellectual property they need to grow their businesses.
To support the development of intellectual property expertise and legal advice for Canada's innovation community, the Government proposes to provide $21.5 million over five years, starting in 2018–19, to Innovation, Science and Economic Development Canada. This funding will improve access for Canadian entrepreneurs to intellectual property legal clinics at universities. It will also enable the creation of a team in the federal government to work with Canadian entrepreneurs to help them develop tailored strategies for using their intellectual property and expanding into international markets.
To support strategic intellectual property tools that enable economic growth, Budget 2018 also proposes to provide $33.8 million over five years, starting in 2018–19, to Innovation, Science and Economic Development Canada, including $4.5 million for the creation of an intellectual property marketplace. This marketplace will be a one-stop, online listing of public sector-owned intellectual property available for licensing or sale to reduce transaction costs for businesses and researchers, and to improve Canadian entrepreneurs' access to public sector-owned intellectual property.
The Government will also consider further measures, including through legislation, in support of the new intellectual property strategy.
Helping All Canadians Harness Intellectual Property
Intellectual property is one of our most valuable resources, and every Canadian business owner should understand how to protect and use it.
To better understand what groups of Canadians are benefiting the most from intellectual property, Budget 2018 proposes to provide Statistics Canada with $2 million over three years to conduct an intellectual property awareness and use survey. This survey will help identify how Canadians understand and use intellectual property, including groups that have traditionally been less likely to use intellectual property, such as women and Indigenous entrepreneurs. The results of the survey should help the Government better meet the needs of these groups through education and awareness initiatives.
The Canadian Intellectual Property Office will also increase the number of education and awareness initiatives that are delivered in partnership with business, intermediaries and academia to ensure Canadians better understand, integrate and take advantage of intellectual property when building their business strategies. This will include targeted initiatives to support underrepresented groups.
Finally, Budget 2018 also proposes to invest $1 million over five years to enable representatives of Canada's Indigenous Peoples to participate in discussions at the World Intellectual Property Organization related to traditional knowledge and traditional cultural expressions, an important form of intellectual property.
It's not wholly clear what they mean by 'intellectual property'. The focus seems to be on patents as they are the only intellectual property (as opposed to copyright and trademarks) singled out in the budget. As for how the 'patent collective' is going to meet all its objectives, this budget supplies no clarity on the matter. On the plus side, I'm glad to see that indigenous peoples' knowledge is being acknowledged as "an important form of intellectual property" and I hope the discussions at the World Intellectual Property Organization are fruitful.
As for the patent situation in Canada (from the report released April 10, 2018),
Over the past decade, the Canadian patent flow in all technical sectors has consistently decreased. Patent flow provides a partial picture of how patents in Canada are exploited. A negative flow represents a deficit of patented inventions owned by Canadian assignees versus the number of patented inventions created by Canadian inventors. The patent flow for all Canadian patents decreased from about −0.04 in 2003 to −0.26 in 2014 (Figure 4.7). This means that there is an overall deficit of 26% of patent ownership in Canada. In other words, fewer patents were owned by Canadian institutions than were invented in Canada.
This is a significant change from 2003 when the deficit was only 4%. The drop is consistent across all technical sectors in the past 10 years, with Mechanical Engineering falling the least, and Electrical Engineering the most (Figure 4.7). At the technical field level, the patent flow dropped significantly in Digital Communication and Telecommunications. For example, the Digital Communication patent flow fell from 0.6 in 2003 to −0.2 in 2014. This fall could be partially linked to Nortel's US$4.5 billion patent sale [emphasis mine] to the Rockstar consortium (which included Apple, BlackBerry, Ericsson, Microsoft, and Sony) (Brickley, 2011). Food Chemistry and Microstructural [?] and Nanotechnology both also showed a significant drop in patent flow. [p. 83 Print; p. 121 PDF]
Despite a fall in the number of parents for 'Digital Communication', we're still doing well according to statistics elsewhere in this report. Is it possible that patents aren't that big a deal? Of course, it's also possible that we are enjoying the benefits of past work and will miss out on future work. (Note: A video of the April 10, 2018 report presentation by Max Blouw features him saying something like that.)
One last note, Nortel died many years ago. Disconcertingly, this report, despite more than one reference to Nortel, never mentions the company's demise.
Boxed text
While the expert panel wasn't tasked to answer certain types of questions, as I've noted earlier they managed to sneak in a few items. One of the strategies they used was putting special inserts into text boxes including this (from the report released April 10, 2018),
Box 4.2
The FinTech Revolution
Financial services is a key industry in Canada. In 2015, the industry accounted for 4.4%
of Canadia jobs and about 7% of Canadian GDP (Burt, 2016). Toronto is the second largest financial services hub in North America and one of the most vibrant research hubs in FinTech. Since 2010, more than 100 start-up companies have been founded in Canada, attracting more than $1 billion in investment (Moffatt, 2016). In 2016 alone, venture-backed investment in Canadian financial technology companies grew by 35% to $137.7 million (Ho, 2017). The Toronto Financial Services Alliance estimates that there are approximately 40,000 ICT specialists working in financial services in Toronto alone.
AI, blockchain, [emphasis mine] and other results of ICT research provide the basis for several transformative FinTech innovations including, for example, decentralized transaction ledgers, cryptocurrencies (e.g., bitcoin), and AI-based risk assessment and fraud detection. These innovations offer opportunities to develop new markets for established financial services firms, but also provide entry points for technology firms to develop competing service offerings, increasing competition in the financial services industry. In response, many financial services companies are increasing their investments in FinTech companies (Breznitz et al., 2015). By their own account, the big five banks invest more than $1 billion annually in R&D of advanced software solutions, including AI-based innovations (J. Thompson, personal communication, 2016). The banks are also increasingly investing in university research and collaboration with start-up companies. For instance, together with several large insurance and financial management firms, all big five banks have invested in the Vector Institute for Artificial Intelligence (Kolm, 2017).
I'm glad to see the mention of blockchain while AI (artificial intelligence) is an area where we have innovated (from the report released April 10, 2018),
AI has attracted researchers and funding since the 1960s; however, there were periods of stagnation in the 1970s and 1980s, sometimes referred to as the "AI winter." During this period, the Canadian Institute for Advanced Research (CIFAR), under the direction of Fraser Mustard, started supporting AI research with a decade-long program called Artificial Intelligence, Robotics and Society, [emphasis mine] which was active from 1983 to 1994. In 2004, a new program called Neural Computation and Adaptive Perception was initiated and renewed twice in 2008 and 2014 under the title, Learning in Machines and Brains. Through these programs, the government provided long-term, predictable support for high- risk research that propelled Canadian researchers to the forefront of global AI development. In the 1990s and early 2000s, Canadian research output and impact on AI were second only to that of the United States (CIFAR, 2016). NSERC has also been an early supporter of AI. According to its searchable grant database, NSERC has given funding to research projects on AI since at least 1991–1992 (the earliest searchable year) (NSERC, 2017a).
The University of Toronto, the University of Alberta, and the Université de Montréal have emerged as international centres for research in neural networks and deep learning, with leading experts such as Geoffrey Hinton and Yoshua Bengio. Recently, these locations have expanded into vibrant hubs for research in AI applications with a diverse mix of specialized research institutes, accelerators, and start-up companies, and growing investment by major international players in AI development, such as Microsoft, Google, and Facebook. Many highly influential AI researchers today are either from Canada or have at some point in their careers worked at a Canadian institution or with Canadian scholars.
As international opportunities in AI research and the ICT industry have grown, many of Canada's AI pioneers have been drawn to research institutions and companies outside of Canada. According to the OECD, Canada's share of patents in AI declined from 2.4% in 2000 to 2005 to 2% in 2010 to 2015. Although Canada is the sixth largest producer of top-cited scientific publications related to machine learning, firms headquartered in Canada accounted for only 0.9% of all AI-related inventions from 2012 to 2014 (OECD, 2017c). Canadian AI researchers, however, remain involved in the core nodes of an expanding international network of AI researchers, most of whom continue to maintain ties with their home institutions. Compared with their international peers, Canadian AI researchers are engaged in international collaborations far more often than would be expected by Canada's level of research output, with Canada ranking fifth in collaboration. [p. 97-98 Print; p. 135-136 PDF]
The only mention of robotics seems to be here in this section and it's only in passing. This is a bit surprising given its global importance. I wonder if robotics has been somehow hidden inside the term artificial intelligence, although sometimes it's vice versa with robot being used to describe artificial intelligence. I'm noticing this trend of assuming the terms are synonymous or interchangeable not just in Canadian publications but elsewhere too. 'nuff said.
Getting back to the matter at hand, t he report does note that patenting (technometric data) is problematic (from the report released April 10, 2018),
The limitations of technometric data stem largely from their restricted applicability across areas of R&D. Patenting, as a strategy for IP management, is similarly limited in not being equally relevant across industries. Trends in patenting can also reflect commercial pressures unrelated to R&D activities, such as defensive or strategic patenting practices. Finally, taxonomies for assessing patents are not aligned with bibliometric taxonomies, though links can be drawn to research publications through the analysis of patent citations. [p. 105 Print; p. 143 PDF]
It's interesting to me that they make reference to many of the same issues that I mention but they seem to forget and don't use that information in their conclusions.
There is one other piece of boxed text I want to highlight (from the report released April 10, 2018),
Open Science: An Emerging Approach to Create New Linkages
Open Science is an umbrella term to describe collaborative and open approaches to
undertaking science, which can be powerful catalysts of innovation. This includes
the development of open collaborative networks among research performers, such
as the private sector, and the wider distribution of research that usually results when
restrictions on use are removed. Such an approach triggers faster translation of ideas
among research partners and moves the boundaries of pre-competitive research to
later, applied stages of research. With research results freely accessible, companies
can focus on developing new products and processes that can be commercialized.
Two Canadian organizations exemplify the development of such models. In June
2017, Genome Canada, the Ontario government, and pharmaceutical companies
invested $33 million in the Structural Genomics Consortium (SGC) (Genome Canada,
2017). Formed in 2004, the SGC is at the forefront of the Canadian open science
movement and has contributed to many key research advancements towards new
treatments (SGC, 2018). McGill University's Montréal Neurological Institute and
Hospital has also embraced the principles of open science. Since 2016, it has been
sharing its research results with the scientific community without restriction, with
the objective of expanding "the impact of brain research and accelerat[ing] the
discovery of ground-breaking therapies to treat patients suffering from a wide range
of devastating neurological diseases" (neuro, n.d.).
This is exciting stuff and I'm happy the panel featured it. (I wrote about the Montréal Neurological Institute initiative in a Jan. 22, 2016 posting.)
More than once, the report notes the difficulties with using bibliometric and technometric data as measures of scientific achievement and progress and open science (along with its cousins, open data and open access) are contributing to the difficulties as James Somers notes in his April 5, 2018 article 'The Scientific Paper is Obsolete' for The Atlantic (Note: Links have been removed),
The scientific paper—the actual form of it—was one of the enabling inventions of modernity. Before it was developed in the 1600s, results were communicated privately in letters, ephemerally in lectures, or all at once in books. There was no public forum for incremental advances. By making room for reports of single experiments or minor technical advances, journals made the chaos of science accretive. Scientists from that point forward became like the social insects: They made their progress steadily, as a buzzing mass.
The earliest papers were in some ways more readable than papers are today. They were less specialized, more direct, shorter, and far less formal. Calculus had only just been invented. Entire data sets could fit in a table on a single page. What little "computation" contributed to the results was done by hand and could be verified in the same way.
The more sophisticated science becomes, the harder it is to communicate results. Papers today are longer than ever and full of jargon and symbols. They depend on chains of computer programs that generate data, and clean up data, and plot data, and run statistical models on data. These programs tend to be both so sloppily written and so central to the results that it's [sic] contributed to a replication crisis, or put another way, a failure of the paper to perform its most basic task: to report what you've actually discovered, clearly enough that someone else can discover it for themselves.
Perhaps the paper itself is to blame. Scientific methods evolve now at the speed of software; the skill most in demand among physicists, biologists, chemists, geologists, even anthropologists and research psychologists, is facility with programming languages and "data science" packages. And yet the basic means of communicating scientific results hasn't changed for 400 years. Papers may be posted online, but they're still text and pictures on a page.
What would you get if you designed the scientific paper from scratch today? A little while ago I spoke to Bret Victor, a researcher who worked at Apple on early user-interface prototypes for the iPad and now runs his own lab in Oakland, California, that studies the future of computing. Victor has long been convinced that scientists haven't yet taken full advantage of the computer. "It's not that different than looking at the printing press, and the evolution of the book," he said. After Gutenberg, the printing press was mostly used to mimic the calligraphy in bibles. It took nearly 100 years of technical and conceptual improvements to invent the modern book. "There was this entire period where they had the new technology of printing, but they were just using it to emulate the old media."Victor gestured at what might be possible when he redesigned a journal article by Duncan Watts and Steven Strogatz, "Collective dynamics of 'small-world' networks." He chose it both because it's one of the most highly cited papers in all of science and because it's a model of clear exposition. (Strogatz is best known for writing the beloved "Elements of Math" column for The New York Times.)
The Watts-Strogatz paper described its key findings the way most papers do, with text, pictures, and mathematical symbols. And like most papers, these findings were still hard to swallow, despite the lucid prose. The hardest parts were the ones that described procedures or algorithms, because these required the reader to "play computer" in their head, as Victor put it, that is, to strain to maintain a fragile mental picture of what was happening with each step of the algorithm.Victor's redesign interleaved the explanatory text with little interactive diagrams that illustrated each step. In his version, you could see the algorithm at work on an example. You could even control it yourself….
For anyone interested in the evolution of how science is conducted and communicated, Somers' article is a fascinating and in depth look at future possibilities.
Subregional R&D
I didn't find this quite as compelling as the last time and that may be due to the fact that there's less information and I think the 2012 report was the first to examine the Canadian R&D scene with a subregional (in their case, provinces) lens. On a high note, this report also covers cities (!) and regions, as well as, provinces.
Here's the conclusion (from the report released April 10, 2018),
Ontario leads Canada in R&D investment and performance. The province accounts for almost half of R&D investment and personnel, research publications and collaborations, and patents. R&D activity in Ontario produces high-quality publications in each of Canada's five R&D strengths, reflecting both the quantity and quality of universities in the province. Quebec lags Ontario in total investment, publications, and patents, but performs as well (citations) or better (R&D intensity) by some measures. Much like Ontario, Quebec researchers produce impactful publications across most of Canada's five R&D strengths. Although it invests an amount similar to that of Alberta, British Columbia does so at a significantly higher intensity. British Columbia also produces more highly cited publications and patents, and is involved in more international research collaborations. R&D in British Columbia and Alberta clusters around Vancouver and Calgary in areas such as physics and ICT and in clinical medicine and energy, respectively. [emphasis mine] Smaller but vibrant R&D communities exist in the Prairies and Atlantic Canada [also referred to as the Maritime provinces or Maritimes] (and, to a lesser extent, in the Territories) in natural resource industries.
Globally, as urban populations expand exponentially, cities are likely to drive innovation and wealth creation at an increasing rate in the future. In Canada, R&D activity clusters around five large cities: Toronto, Montréal, Vancouver, Ottawa, and Calgary. These five cities create patents and high-tech companies at nearly twice the rate of other Canadian cities. They also account for half of clusters in the services sector, and many in advanced manufacturing.
Many clusters relate to natural resources and long-standing areas of economic and research strength. Natural resource clusters have emerged around the location of resources, such as forestry in British Columbia, oil and gas in Alberta, agriculture in Ontario, mining in Quebec, and maritime resources in Atlantic Canada. The automotive, plastics, and steel industries have the most individual clusters as a result of their economic success in Windsor, Hamilton, and Oshawa. Advanced manufacturing industries tend to be more concentrated, often located near specialized research universities. Strong connections between academia and industry are often associated with these clusters. R&D activity is distributed across the country, varying both between and within regions. It is critical to avoid drawing the wrong conclusion from this fact. This distribution does not imply the existence of a problem that needs to be remedied. Rather, it signals the benefits of diverse innovation systems, with differentiation driven by the needs of and resources available in each province. [pp. 132-133 Print; pp. 170-171 PDF]
Intriguingly, there's no mention that in British Columbia (BC), there are leading areas of research: Visual & Performing Arts, Psychology & Cognitive Sciences, and Clinical Medicine (according to the table on p. 117 Print, p. 153 PDF).
As I said and hinted earlier, we've got brains; they're just not the kind of brains that command respect.
My hat's off to the expert panel and staff of the Council of Canadian Academies. Combining two previous reports into one could not have been easy. As well, kudos to their attempts to broaden the discussion by mentioning initiative such as open science and for emphasizing the problems with bibliometrics, technometrics, and other measures. I have covered only parts of this assessment, (Competing in a Global Innovation Economy: The Current State of R&D in Canada), there's a lot more to it including a substantive list of reference materials (bibliography).
While I have argued that perhaps the situation isn't quite as bad as the headlines and statistics may suggest, there are some concerning trends for Canadians but we have to acknowledge that many countries have stepped up their research game and that's good for all of us. You don't get better at anything unless you work with and play with others who are better than you are. For example, both India and Italy surpassed us in numbers of published research papers. We slipped from 7th place to 9th. Thank you, Italy and India. (And, Happy 'Italian Research in the World Day' on April 15, 2018, the day's inaugural year. In Italian: Piano Straordinario "Vivere all'Italiana" – Giornata della ricerca Italiana nel mondo.)
Unfortunately, the reading is harder going than previous R&D assessments in the CCA catalogue. And in the end, I can't help thinking we're just a little bit like Hedy Lamarr. Not really appreciated in all of our complexities although the expert panel and staff did try from time to time. Perhaps the government needs to find better ways of asking the questions.
***ETA April 12, 2018 at 1500 PDT: Talking about missing the obvious! I've been ranting on about how research strength in visual and performing arts and in philosophy and theology, etc. is perfectly fine and could lead to 'traditional' science breakthroughs without underlining the point by noting that Antheil was a musician, Lamarr was as an actress and they set the foundation for work by electrical engineers (or people with that specialty) for their signature work leading to WiFi, etc.***
There is, by the way, a Hedy-Canada connection. In 1998, she sued Canadian software company Corel, for its unauthorized use of her image on their Corel Draw 8 product packaging. She won.
For those who'd like to see and hear the April 10, 2017 launch for "Competing in a Global Innovation Economy: The Current State of R&D in Canada" or the Third Assessment as I think of it, go here.
The report can be found here.
For anyone curious about 'Bombshell: The Hedy Lamarr Story' to be broadcast on May 18, 2018 as part of PBS's American Masters series, there's this trailer,
For the curious, I did find out more about the Hedy Lamarr and Corel Draw. John Lettice's December 2, 1998 article The Rgister describes the suit and her subsequent victory in less than admiring terms,
Our picture doesn't show glamorous actress Hedy Lamarr, who yesterday [Dec. 1, 1998] came to a settlement with Corel over the use of her image on Corel's packaging. But we suppose that following the settlement we could have used a picture of Corel's packaging. Lamarr sued Corel earlier this year over its use of a CorelDraw image of her. The picture had been produced by John Corkery, who was 1996 Best of Show winner of the Corel World Design Contest. Corel now seems to have come to an undisclosed settlement with her, which includes a five-year exclusive (oops — maybe we can't use the pack-shot then) licence to use "the lifelike vector illustration of Hedy Lamarr on Corel's graphic software packaging". Lamarr, bless 'er, says she's looking forward to the continued success of Corel Corporation, …
There's this excerpt from a Sept. 21, 2015 posting (a pictorial essay of Lamarr's life) by Shahebaz Khan on The Blaze Blog,
6. CorelDRAW:
For several years beginning in 1997, the boxes of Corel DRAW's software suites were graced by a large Corel-drawn image of Lamarr. The picture won Corel DRAW's yearly software suite cover design contest in 1996. Lamarr sued Corel for using the image without her permission. Corel countered that she did not own rights to the image. The parties reached an undisclosed settlement in 1998.
There's also a Nov. 23, 1998 Corel Draw 8 product review by Mike Gorman on mymac.com, which includes a screenshot of the packaging that precipitated the lawsuit. Once they settled, it seems Corel used her image at least one more time.
This entry was posted in intellectual property, nanotechnology, science, science policy, Technology and tagged 2012 S&T report, 2018 Canadian federal budget, aerospace, agriculture, AI, AI winter, AI-based fraud detection, AI-based risk assessment, Alberta, Alexandra Dean, and telecommunications) research, Apple, artificial intelligence, Artificial Intelligence Robotics and Society, astronomy, Atlantic Canada, automotive, bibliometrics, biotechnology, Blackberry, blockchain, Bluetooth, Bombshell: The Hedy Lamarr Story, branch plant economy, Brazil, Bret Victor, British Columbia, Calgary, Canada, Canadian entrepreneurs, Canadian Institute for Advanced Research (CIFAR), Canadian Intellectual Property Office, Canadian open science, Catalyzing Canada's Digital Economy (2010), chemistry, China, cities, civil engineering, cognitive sciences, Collective dynamics of 'small-world' networks, communications, Competing in a Global Innovation Economy: The Current State of R and D in Canada, computation, computer technology, Corel, Corel Corporation, Corel Draw 8 product packaging, Council of Canadian Academies (CCA), cryptocurrencies, data science packages, digital communication, Duncan Watts, earth sciences, electrical engineering, Elements of Math, enabling and strategic technologies, engineering, environment, environmental sciences, Ericsson, Facebook, financial services, FinTech, food chemistry, forestry, Fraser Mustard, future of computing, Genome Canada, Geoffrey Hinton, George Antheil, Google, Government of Canada, GPS, Gutenberg, Hamilton, health, health services, Hedy Lamarr, ICT, ICT (information, India, Information and Communication Technologies (ICT), Informing Research Choices: Indicators and Judgment (2012), Innovation and Business Strategy: Why Canada Falls Short (2009), Innovation Science and Economic Development Canada, Intellectual Property Strategy, inventor, Iran, Italian Research in the World Day, Italy, James Somers, John Lettice, Learning in Machines and Brain, machine learning, Maritime provinces, maritime resources, Maritimes, materials science, mathematics, McGill University, mechanical engineering, medical informatics, Microsoft, Mike Gorman, mining, Montréal, Montréal Neuro, Montréal Neurological Institute initiative, movie star, nanoscience and nanotechnology, Natural Philosophy, natural sciences, Natural Sciences and Engineering Research Council (NSERC), Nortel, Northwest Territories, OECD, oil and gas, Ontario, Ontario government, open access, open collaborative networks, open data, open science, optoelectronics, Organization for Economic Cooperation and Development, Oshawa, other special machines, Ottawa, Paradox Lost: Explaining Canada's Research Strength and Innovation Weakness (2013), patent collective, patents, performing arts, personalized medicine, pharmaceutical companies, Pharmaceuticals, philosophy, photonics, physical sciences, physics, Piano Straordinario Vivere all'Italiana - Giornata della ricerca Italiana nel mondo, plastics, Prairies, psychology, public health, Quebec, R&D, regenerative medicine, research and development, Rockstar consortium, s Montréal Neurological Institute and Hospital, science technology engineering and mathematics, Shahebaz Khan, shared intellectual property, Sony, South Korea, statistics, Statistics Canada, steel industries, STEM, Steven Strogatz, Structural Genomics Consortium (SGC), subregional R and D, technometrics, telecommunications, The Scientific Paper is Obsolete, The State of Industrial R&D in Canada (2013), The State of Science and Technology in Canada 2006, The State of Science and Technology in Canada 2012, theology, Third assessment of The State of Science and Technology and Industrial Research and Development in Canada, Third assessment on the State of S&T and IR&D, Toronto, Toronto Financial Services Alliance, United States, Universite de Montreal, University of Alberta, University of Toronto, US, US Navy, Vancouver, Vector Institute for Artificial Intelligence, visual, Watts-Strogatz paper, Wi-Fi, Windsor, World Intellectual Property Organization, Yoshua Bengio on April 12, 2018 by Maryse de la Giroday.
Before launching into the assessment, a brief explanation of my theme: Hedy Lamarr was considered to be one of the great beauties of her day,
"Ziegfeld Girl" Hedy Lamarr 1941 MGM *M.V.
Titles: Ziegfeld Girl
People: Hedy Lamarr
Image courtesy mptvimages.com [downloaded from https://www.imdb.com/title/tt0034415/mediaviewer/rm1566611456]
Aside from starring in Hollywood movies and, before that, movies in Europe, she was also an inventor and not just any inventor (from a Dec. 4, 2017 article by Laura Barnett for The Guardian), Note: Links have been removed,
Let's take a moment to reflect on the mercurial brilliance of Hedy Lamarr. Not only did the Vienna-born actor flee a loveless marriage to a Nazi arms dealer to secure a seven-year, $3,000-a-week contract with MGM, and become (probably) the first Hollywood star to simulate a female orgasm on screen – she also took time out to invent a device that would eventually revolutionise mobile communications.
As described in unprecedented detail by the American journalist and historian Richard Rhodes in his new book, Hedy's Folly, Lamarr and her business partner, the composer George Antheil, were awarded a patent in 1942 for a "secret communication system". It was meant for radio-guided torpedoes, and the pair gave to the US Navy. It languished in their files for decades before eventually becoming a constituent part of GPS, Wi-Fi and Bluetooth technology.
(The article goes on to mention other celebrities [Marlon Brando, Barbara Cartland, Mark Twain, etc] and their inventions.)
Lamarr's work as an inventor was largely overlooked until the 1990's when the technology community turned her into a 'cultish' favourite and from there her reputation grew and acknowledgement increased culminating in Rhodes' book and the documentary by Alexandra Dean, 'Bombshell: The Hedy Lamarr Story (to be broadcast as part of PBS's American Masters series on May 18, 2018).
Canada as Hedy Lamarr
There are some parallels to be drawn between Canada's S&T and R&D (science and technology; research and development) and Ms. Lamarr. Chief amongst them, we're not always appreciated for our brains. Not even by people who are supposed to know better such as the experts on the panel for the 'Third assessment of The State of Science and Technology and Industrial Research and Development in Canada' (proper title: Competing in a Global Innovation Economy: The Current State of R&D in Canada) from the Expert Panel on the State of Science and Technology and Industrial Research and Development in Canada.
Before exploring the comparison to Hedy Lamarr further, here's a bit more about the history of this latest assessment from the Council of Canadian Academies (CCA), from the report released April 10, 2018,
This assessment of Canada's performance indicators in science, technology, research, and innovation comes at an opportune time. The Government of Canada has expressed a renewed commitment in several tangible ways to this broad domain of activity including its Innovation and Skills Plan, the announcement of five superclusters, its appointment of a new Chief Science Advisor, and its request for the Fundamental Science Review. More specifically, the 2018 Federal Budget demonstrated the government's strong commitment to research and innovation with historic investments in science.
The CCA has a decade-long history of conducting evidence-based assessments about Canada's research and development activities, producing seven assessments of relevance:
•The State of Science and Technology in Canada (2006) [emphasis mine]
•Innovation and Business Strategy: Why Canada Falls Short (2009)
•Catalyzing Canada's Digital Economy (2010)
•Informing Research Choices: Indicators and Judgment (2012)
•The State of Industrial R&D in Canada (2013) [emphasis mine]
•Paradox Lost: Explaining Canada's Research Strength and Innovation Weakness (2013)
Using similar methods and metrics to those in The State of Science and Technology in Canada (2012) and The State of Industrial R&D in Canada (2013), this assessment tells a similar and familiar story: Canada has much to be proud of, with world-class researchers in many domains of knowledge, but the rest of the world is not standing still. Our peers are also producing high quality results, and many countries are making significant commitments to supporting research and development that will position them to better leverage their strengths to compete globally. Canada will need to take notice as it determines how best to take action. This assessment provides valuable material for that conversation to occur, whether it takes place in the lab or the legislature, the bench or the boardroom. We also hope it will be used to inform public discussion. [p. ix Print, p. 11 PDF]
This latest assessment succeeds the general 2006 and 2012 reports, which were mostly focused on academic research, and combines it with an assessment of industrial research, which was previously separate. Also, this third assessment's title (Competing in a Global Innovation Economy: The Current State of R&D in Canada) makes what was previously quietly declared in the text, explicit from the cover onwards. It's all about competition, despite noises such as the 2017 Naylor report (Review of fundamental research) about the importance of fundamental research.
One other quick comment, I did wonder in my July 1, 2016 posting (featuring the announcement of the third assessment) how combining two assessments would impact the size of the expert panel and the size of the final report,
Given the size of the 2012 assessment of science and technology at 232 pp. (PDF) and the 2013 assessment of industrial research and development at 220 pp. (PDF) with two expert panels, the imagination boggles at the potential size of the 2016 expert panel and of the 2016 assessment combining the two areas.
I got my answer with regard to the panel as noted in my Oct. 20, 2016 update (which featured a list of the members),
A few observations, given the size of the task, this panel is lean. As well, there are three women in a group of 13 (less than 25% representation) in 2016? It's Ontario and Québec-dominant; only BC and Alberta rate a representative on the panel. I hope they will find ways to better balance this panel and communicate that 'balanced story' to the rest of us. On the plus side, the panel has representatives from the humanities, arts, and industry in addition to the expected representatives from the sciences.
The imbalance I noted then was addressed, somewhat, with the selection of the reviewers (from the report released April 10, 2018),
The CCA wishes to thank the following individuals for their review of this report:
Ronald Burnett, C.M., O.B.C., RCA, Chevalier de l'ordre des arts et des
lettres, President and Vice-Chancellor, Emily Carr University of Art and Design
(Vancouver, BC)
Michelle N. Chretien, Director, Centre for Advanced Manufacturing and Design
Technologies, Sheridan College; Former Program and Business Development
Manager, Electronic Materials, Xerox Research Centre of Canada (Brampton,
Lisa Crossley, CEO, Reliq Health Technologies, Inc. (Ancaster, ON)
Natalie Dakers, Founding President and CEO, Accel-Rx Health Sciences
Accelerator (Vancouver, BC)
Fred Gault, Professorial Fellow, United Nations University-MERIT (Maastricht,
Netherlands)
Patrick D. Germain, Principal Engineering Specialist, Advanced Aerodynamics,
Bombardier Aerospace (Montréal, QC)
Robert Brian Haynes, O.C., FRSC, FCAHS, Professor Emeritus, DeGroote
School of Medicine, McMaster University (Hamilton, ON)
Susan Holt, Chief, Innovation and Business Relationships, Government of
New Brunswick (Fredericton, NB)
Pierre A. Mohnen, Professor, United Nations University-MERIT and Maastricht
University (Maastricht, Netherlands)
Peter J. M. Nicholson, C.M., Retired; Former and Founding President and
CEO, Council of Canadian Academies (Annapolis Royal, NS)
Raymond G. Siemens, Distinguished Professor, English and Computer Science
and Former Canada Research Chair in Humanities Computing, University of
Victoria (Victoria, BC) [pp. xii- xiv Print; pp. 15-16 PDF]
The proportion of women to men as reviewers jumped up to about 36% (4 of 11 reviewers) and there are two reviewers from the Maritime provinces. As usual, reviewers external to Canada were from Europe. Although this time, they came from Dutch institutions rather than UK or German institutions. Interestingly and unusually, there was no one from a US institution. When will they start using reviewers from other parts of the world?
As for the report itself, it is 244 pp. (PDF). (For the really curious, I have a December 15, 2016 post featuring my comments on the preliminary data for the third assessment.)
To sum up, they had a lean expert panel tasked with bringing together two inquiries and two reports. I imagine that was daunting. Good on them for finding a way to make it manageable.
Bibliometrics, patents, and a survey
I wish more attention had been paid to some of the issues around open science, open access, and open data, which are changing how science is being conducted. (I have more about this from an April 5, 2018 article by James Somers for The Atlantic but more about that later.) If I understand rightly, they may not have been possible due to the nature of the questions posed by the government when requested the assessment.
As was done for the second assessment, there is an acknowledgement that the standard measures/metrics (bibliometrics [no. of papers published, which journals published them; number of times papers were cited] and technometrics [no. of patent applications, etc.] of scientific accomplishment and progress are not the best and new approaches need to be developed and adopted (from the report released April 10, 2018),
It is also worth noting that the Panel itself recognized the limits that come from using traditional historic metrics. Additional approaches will be needed the next time this assessment is done. [p. ix Print; p. 11 PDF]
For the second assessment and as a means of addressing some of the problems with metrics, the panel decided to take a survey which the panel for the third assessment has also done (from the report released April 10, 2018),
The Panel relied on evidence from multiple sources to address its charge, including a literature review and data extracted from statistical agencies and organizations such as Statistics Canada and the OECD. For international comparisons, the Panel focused on OECD countries along with developing countries that are among the top 20 producers of peer-reviewed research publications (e.g., China, India, Brazil, Iran, Turkey). In addition to the literature review, two primary research approaches informed the Panel's assessment:
•a comprehensive bibliometric and technometric analysis of Canadian research publications and patents; and,
•a survey of top-cited researchers around the world.
Despite best efforts to collect and analyze up-to-date information, one of the Panel's findings is that data limitations continue to constrain the assessment of R&D activity and excellence in Canada. This is particularly the case with industrial R&D and in the social sciences, arts, and humanities. Data on industrial R&D activity continue to suffer from time lags for some measures, such as internationally comparable data on R&D intensity by sector and industry. These data also rely on industrial categories (i.e., NAICS and ISIC codes) that can obscure important trends, particularly in the services sector, though Statistics Canada's recent revisions to how this data is reported have improved this situation. There is also a lack of internationally comparable metrics relating to R&D outcomes and impacts, aside from those based on patents.
For the social sciences, arts, and humanities, metrics based on journal articles and other indexed publications provide an incomplete and uneven picture of research contributions. The expansion of bibliometric databases and methodological improvements such as greater use of web-based metrics, including paper views/downloads and social media references, will support ongoing, incremental improvements in the availability and accuracy of data. However, future assessments of R&D in Canada may benefit from more substantive integration of expert review, capable of factoring in different types of research outputs (e.g., non-indexed books) and impacts (e.g., contributions to communities or impacts on public policy). The Panel has no doubt that contributions from the humanities, arts, and social sciences are of equal importance to national prosperity. It is vital that such contributions are better measured and assessed. [p. xvii Print; p. 19 PDF]
My reading: there's a problem and we're not going to try and fix it this time. Good luck to those who come after us. As for this line: "The Panel has no doubt that contributions from the humanities, arts, and social sciences are of equal importance to national prosperity." Did no one explain that when you use 'no doubt', you are introducing doubt? It's a cousin to 'don't take this the wrong way' and 'I don't mean to be rude but …' .
This is somewhat encouraging (from the report released April 10, 2018),
Canada's international reputation for its capacity to participate in cutting-edge R&D is strong, with 60% of top-cited researchers surveyed internationally indicating that Canada hosts world-leading infrastructure or programs in their fields. This share increased by four percentage points between 2012 and 2017. Canada continues to benefit from a highly educated population and deep pools of research skills and talent. Its population has the highest level of educational attainment in the OECD in the proportion of the population with
a post-secondary education. However, among younger cohorts (aged 25 to 34), Canada has fallen behind Japan and South Korea. The number of researchers per capita in Canada is on a par with that of other developed countries, andincreased modestly between 2004 and 2012. Canada's output of PhD graduates has also grown in recent years, though it remains low in per capita terms relative to many OECD countries. [pp. xvii-xviii; pp. 19-20]
Don't let your head get too big
Most of the report observes that our international standing is slipping in various ways such as this (from the report released April 10, 2018),
In contrast, the number of R&D personnel employed in Canadian businesses
dropped by 20% between 2008 and 2013. This is likely related to sustained and
ongoing decline in business R&D investment across the country. R&D as a share
of gross domestic product (GDP) has steadily declined in Canada since 2001,
and now stands well below the OECD average (Figure 1). As one of few OECD
countries with virtually no growth in total national R&D expenditures between
2006 and 2015, Canada would now need to more than double expenditures to
achieve an R&D intensity comparable to that of leading countries.
Low and declining business R&D expenditures are the dominant driver of this
trend; however, R&D spending in all sectors is implicated. Government R&D
expenditures declined, in real terms, over the same period. Expenditures in the
higher education sector (an indicator on which Canada has traditionally ranked
highly) are also increasing more slowly than the OECD average. Significant
erosion of Canada's international competitiveness and capacity to participate
in R&D and innovation is likely to occur if this decline and underinvestment
continue.
Between 2009 and 2014, Canada produced 3.8% of the world's research
publications, ranking ninth in the world. This is down from seventh place for
the 2003–2008 period. India and Italy have overtaken Canada although the
difference between Italy and Canada is small. Publication output in Canada grew
by 26% between 2003 and 2014, a growth rate greater than many developed
countries (including United States, France, Germany, United Kingdom, and
Japan), but below the world average, which reflects the rapid growth in China
and other emerging economies. Research output from the federal government,
particularly the National Research Council Canada, dropped significantly
between 2009 and 2014.(emphasis mine) [p. xviii Print; p. 20 PDF]
For anyone unfamiliar with Canadian politics, 2009 – 2014 were years during which Stephen Harper's Conservatives formed the government. Justin Trudeau's Liberals were elected to form the government in late 2015.
During Harper's years in government, the Conservatives were very interested in changing how the National Research Council of Canada operated and, if memory serves, the focus was on innovation over research. Consequently, the drop in their research output is predictable.
Given my interest in nanotechnology and other emerging technologies, this popped out (from the report released April 10, 2018),
When it comes to research on most enabling and strategic technologies, however, Canada lags other countries. Bibliometric evidence suggests that, with the exception of selected subfields in Information and Communication Technologies (ICT) such as Medical Informatics and Personalized Medicine, Canada accounts for a relatively small share of the world's research output for promising areas of technology development. This is particularly true for Biotechnology, Nanotechnology, and Materials science [emphasis mine]. Canada's research impact, as reflected by citations, is also modest in these areas. Aside from Biotechnology, none of the other subfields in Enabling and Strategic Technologies has an ARC rank among the top five countries. Optoelectronics and photonics is the next highest ranked at 7th place, followed by Materials, and Nanoscience and Nanotechnology, both of which have a rank of 9th. Even in areas where Canadian researchers and institutions played a seminal role in early research (and retain a substantial research capacity), such as Artificial Intelligence and Regenerative Medicine, Canada has lost ground to other countries.
Arguably, our early efforts in artificial intelligence wouldn't have garnered us much in the way of ranking and yet we managed some cutting edge work such as machine learning. I'm not suggesting the expert panel should have or could have found some way to measure these kinds of efforts but I'm wondering if there could have been some acknowledgement in the text of the report. I'm thinking a couple of sentences in a paragraph about the confounding nature of scientific research where areas that are ignored for years and even decades then become important (e.g., machine learning) but are not measured as part of scientific progress until after they are universally recognized.
Still, point taken about our diminishing returns in 'emerging' technologies and sciences (from the report released April 10, 2018),
The impression that emerges from these data is sobering. With the exception of selected ICT subfields, such as Medical Informatics, bibliometric evidence does not suggest that Canada excels internationally in most of these research areas. In areas such as Nanotechnology and Materials science, Canada lags behind other countries in levels of research output and impact, and other countries are outpacing Canada's publication growth in these areas — leading to declining shares of world publications. Even in research areas such as AI, where Canadian researchers and institutions played a foundational role, Canadian R&D activity is not keeping pace with that of other countries and some researchers trained in Canada have relocated to other countries (Section 4.4.1). There are isolated exceptions to these trends, but the aggregate data reviewed by this Panel suggest that Canada is not currently a world leader in research on most emerging technologies.
The Hedy Lamarr treatment
We have 'good looks' (arts and humanities) but not the kind of brains (physical sciences and engineering) that people admire (from the report released April 10, 2018),
Canada, relative to the world, specializes in subjects generally referred to as the
humanities and social sciences (plus health and the environment), and does
not specialize as much as others in areas traditionally referred to as the physical
sciences and engineering. Specifically, Canada has comparatively high levels
of research output in Psychology and Cognitive Sciences, Public Health and
Health Services, Philosophy and Theology, Earth and Environmental Sciences,
and Visual and Performing Arts. [emphases mine] It accounts for more than 5% of world researchin these fields. Conversely, Canada has lower research output than expected
in Chemistry, Physics and Astronomy, Enabling and Strategic Technologies,
Engineering, and Mathematics and Statistics. The comparatively low research
output in core areas of the natural sciences and engineering is concerning,
and could impair the flexibility of Canada's research base, preventing research
institutions and researchers from being able to pivot to tomorrow's emerging
research areas. [p. xix Print; p. 21 PDF]
Couldn't they have used a more buoyant tone? After all, science was known as 'natural philosophy' up until the 19th century. As for visual and performing arts, let's include poetry as a performing and literary art (both have been the case historically and cross-culturally) and let's also note that one of the great physics texts, (De rerum natura by Lucretius) was a multi-volume poem (from Lucretius' Wikipedia entry; Note: Links have been removed).
His poem De rerum natura (usually translated as "On the Nature of Things" or "On the Nature of the Universe") transmits the ideas of Epicureanism, which includes Atomism [the concept of atoms forming materials] and psychology. Lucretius was the first writer to introduce Roman readers to Epicurean philosophy.[15] The poem, written in some 7,400 dactylic hexameters, is divided into six untitled books, and explores Epicurean physics through richly poetic language and metaphors. Lucretius presents the principles of atomism; the nature of the mind and soul; explanations of sensation and thought; the development of the world and its phenomena; and explains a variety of celestial and terrestrial phenomena. The universe described in the poem operates according to these physical principles, guided by fortuna, "chance", and not the divine intervention of the traditional Roman deities.[16]
Should you need more proof that the arts might have something to contribute to physical sciences, there's this in my March 7, 2018 posting,
It's not often you see research that combines biologically inspired engineering and a molecular biophysicist with a professional animator who worked at Peter Jackson's (Lord of the Rings film trilogy, etc.) Park Road Post film studio. An Oct. 18, 2017 news item on ScienceDaily describes the project,
Like many other scientists, Don Ingber, M.D., Ph.D., the Founding Director of the Wyss Institute, [emphasis mine] is concerned that non-scientists have become skeptical and even fearful of his field at a time when technology can offer solutions to many of the world's greatest problems. "I feel that there's a huge disconnect between science and the public because it's depicted as rote memorization in schools, when by definition, if you can memorize it, it's not science," says Ingber, who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children's Hospital, and Professor of Bioengineering at the Harvard Paulson School of Engineering and Applied Sciences (SEAS). [emphasis mine] "Science is the pursuit of the unknown. We have a responsibility to reach out to the public and convey that excitement of exploration and discovery, and fortunately, the film industry is already great at doing that."
"Not only is our physics-based simulation and animation system as good as other data-based modeling systems, it led to the new scientific insight [emphasis mine] that the limited motion of the dynein hinge focuses the energy released by ATP hydrolysis, which causes dynein's shape change and drives microtubule sliding and axoneme motion," says Ingber. "Additionally, while previous studies of dynein have revealed the molecule's two different static conformations, our animation visually depicts one plausible way that the protein can transition between those shapes at atomic resolution, which is something that other simulations can't do. The animation approach also allows us to visualize how rows of dyneins work in unison, like rowers pulling together in a boat, which is difficult using conventional scientific simulation approaches."
It comes down to how we look at things. Yes, physical sciences and engineering are very important. If the report is to be believed we have a very highly educated population and according to PISA scores our students rank highly in mathematics, science, and reading skills. (For more information on Canada's latest PISA scores from 2015 see this OECD page. As for PISA itself, it's an OECD [Organization for Economic Cooperation and Development] programme where 15-year-old students from around the world are tested on their reading, mathematics, and science skills, you can get some information from my Oct. 9, 2013 posting.)
Is it really so bad that we choose to apply those skills in fields other than the physical sciences and engineering? It's a little bit like Hedy Lamarr's problem except instead of being judged for our looks and having our inventions dismissed, we're being judged for not applying ourselves to physical sciences and engineering and having our work in other closely aligned fields dismissed as less important.
Canada's Industrial R&D: an oft-told, very sad story
Bemoaning the state of Canada's industrial research and development efforts has been a national pastime as long as I can remember. Here's this from the report released April 10, 2018,
There has been a sustained erosion in Canada's industrial R&D capacity and competitiveness. Canada ranks 33rd among leading countries on an index assessing the magnitude, intensity, and growth of industrial R&D expenditures. Although Canada is the 11th largest spender, its industrial R&D intensity (0.9%) is only half the OECD average and total spending is declining (−0.7%). Compared with G7 countries, the Canadian portfolio of R&D investment is more concentrated in industries that are intrinsically not as R&D intensive. Canada invests more heavily than the G7 average in oil and gas, forestry, machinery and equipment, and finance where R&D has been less central to business strategy than in many other industries. … About 50% of Canada's industrial R&D spending is in high-tech sectors (including industries such as ICT, aerospace, pharmaceuticals, and automotive) compared with the G7 average of 80%. Canadian Business Enterprise Expenditures on R&D (BERD) intensity is also below the OECD average in these sectors. In contrast, Canadian investment in low and medium-low tech sectors is substantially higher than the G7 average. Canada's spending reflects both its long-standing industrial structure and patterns of economic activity.
R&D investment patterns in Canada appear to be evolving in response to global and domestic shifts. While small and medium-sized enterprises continue to perform a greater share of industrial R&D in Canada than in the United States, between 2009 and 2013, there was a shift in R&D from smaller to larger firms. Canada is an increasingly attractive place to conduct R&D. Investment by foreign-controlled firms in Canada has increased to more than 35% of total R&D investment, with the United States accounting for more than half of that. [emphasis mine] Multinational enterprises seem to be increasingly locating some of their R&D operations outside their country of ownership, possibly to gain proximity to superior talent. Increasing foreign-controlled R&D, however, also could signal a long-term strategic loss of control over intellectual property (IP) developed in this country, ultimately undermining the government's efforts to support high-growth firms as they scale up. [pp. xxii-xxiii Print; pp. 24-25 PDF]
Canada has been known as a 'branch plant' economy for decades. For anyone unfamiliar with the term, it means that companies from other countries come here, open up a branch and that's how we get our jobs as we don't have all that many large companies here. Increasingly, multinationals are locating R&D shops here.
While our small to medium size companies fund industrial R&D, it's large companies (multinationals) which can afford long-term and serious investment in R&D. Luckily for companies from other countries, we have a well-educated population of people looking for jobs.
In 2017, we opened the door more widely so we can scoop up talented researchers and scientists from other countries, from a June 14, 2017 article by Beckie Smith for The PIE News,
Universities have welcomed the inclusion of the work permit exemption for academic stays of up to 120 days in the strategy, which also introduces expedited visa processing for some highly skilled professions.
Foreign researchers working on projects at a publicly funded degree-granting institution or affiliated research institution will be eligible for one 120-day stay in Canada every 12 months.
And universities will also be able to access a dedicated service channel that will support employers and provide guidance on visa applications for foreign talent.
The Global Skills Strategy, which came into force on June 12 [2017], aims to boost the Canadian economy by filling skills gaps with international talent.
As well as the short term work permit exemption, the Global Skills Strategy aims to make it easier for employers to recruit highly skilled workers in certain fields such as computer engineering.
"Employers that are making plans for job-creating investments in Canada will often need an experienced leader, dynamic researcher or an innovator with unique skills not readily available in Canada to make that investment happen," said Ahmed Hussen, Minister of Immigration, Refugees and Citizenship.
"The Global Skills Strategy aims to give those employers confidence that when they need to hire from abroad, they'll have faster, more reliable access to top talent."
Coincidentally, Microsoft, Facebook, Google, etc. have announced, in 2017, new jobs and new offices in Canadian cities. There's a also Chinese multinational telecom company Huawei Canada which has enjoyed success in Canada and continues to invest here (from a Jan. 19, 2018 article about security concerns by Matthew Braga for the Canadian Broadcasting Corporation (CBC) online news,
For the past decade, Chinese tech company Huawei has found no shortage of success in Canada. Its equipment is used in telecommunications infrastructure run by the country's major carriers, and some have sold Huawei's phones.
The company has struck up partnerships with Canadian universities, and say it is investing more than half a billion dollars in researching next generation cellular networks here. [emphasis mine]
While I'm not thrilled about using patents as an indicator of progress, this is interesting to note (from the report released April 10, 2018),
Canada produces about 1% of global patents, ranking 18th in the world. It lags further behind in trademark (34th) and design applications (34th). Despite relatively weak performance overall in patents, Canada excels in some technical fields such as Civil Engineering, Digital Communication, Other Special Machines, Computer Technology, and Telecommunications. [emphases mine] Canada is a net exporter of patents, which signals the R&D strength of some technology industries. It may also reflect increasing R&D investment by foreign-controlled firms. [emphasis mine] [p. xxiii Print; p. 25 PDF]
Getting back to my point, we don't have large companies here. In fact, the dream for most of our high tech startups is to build up the company so it's attractive to buyers, sell, and retire (hopefully before the age of 40). Strangely, the expert panel doesn't seem to share my insight into this matter,
Canada's combination of high performance in measures of research output and impact, and low performance on measures of industrial R&D investment and innovation (e.g., subpar productivity growth), continue to be viewed as a paradox, leading to the hypothesis that barriers are impeding the flow of Canada's research achievements into commercial applications. The Panel's analysis suggests the need for a more nuanced view. The process of transforming research into innovation and wealth creation is a complex multifaceted process, making it difficult to point to any definitive cause of Canada's deficit in R&D investment and productivity growth. Based on the Panel's interpretation of the evidence, Canada is a highly innovative nation, but significant barriers prevent the translation of innovation into wealth creation. The available evidence does point to a number of important contributing factors that are analyzed in this report. Figure 5 represents the relationships between R&D, innovation, and wealth creation.
The Panel concluded that many factors commonly identified as points of concern do not adequately explain the overall weakness in Canada's innovation performance compared with other countries. [emphasis mine] Academia-business linkages appear relatively robust in quantitative terms given the extent of cross-sectoral R&D funding and increasing academia-industry partnerships, though the volume of academia-industry interactions does not indicate the nature or the quality of that interaction, nor the extent to which firms are capitalizing on the research conducted and the resulting IP. The educational system is high performing by international standards and there does not appear to be a widespread lack of researchers or STEM (science, technology, engineering, and mathematics) skills. IP policies differ across universities and are unlikely to explain a divergence in research commercialization activity between Canadian and U.S. institutions, though Canadian universities and governments could do more to help Canadian firms access university IP and compete in IP management and strategy. Venture capital availability in Canada has improved dramatically in recent years and is now competitive internationally, though still overshadowed by Silicon Valley. Technology start-ups and start-up ecosystems are also flourishing in many sectors and regions, demonstrating their ability to build on research advances to develop and deliver innovative products and services.
You'll note there's no mention of a cultural issue where start-ups are designed for sale as soon as possible and this isn't new. Years ago, there was an accounting firm that published a series of historical maps (the last one I saw was in 2005) of technology companies in the Vancouver region. Technology companies were being developed and sold to large foreign companies from the 19th century to present day.
This entry was posted in intellectual property, nanotechnology, science, science policy, Technology and tagged Accel-Rx Health Sciences, aerospace, Ahmed Hussen, AI, Alexandra Dean, artificial intelligence, arts, astronomy, atomism, automotive, Barbara Cartland, Beckie Smith, bibliometrics, biotechnology, Bluetooth, Bombardier Aerospace, Bombshell: The Hedy Lamarr Story, Boston Children's Hospital, branch plant economy, Brazil, Canada, Catalyzing Canada's Digital Economy (2010), CCA, CEO, chemistry, Chief Science Advisor, China, civil engineering, cognitive sciences, Competing in a Global Innovation Economy: The Current State of R and D in Canada, computer technology, Council of Canadian Academies (CCA), De rerum natura, digital communication, Don Ingber, earth sciences, Emily Carr University of Art and Design, enabling and strategic technologies, engineering, environment, environmental sciences, Epicureanism, Expert Panel on the State of Science and Technology and Industrial Research and Development in Canada, Facebook, France, Fred Gault, Fundamental Science Review, George Antheil, Germany, Global Skills Strategy, Google, Government of Canada, Government of New Brunswick, GPS, Harvard Medical School, Harvard Paulson School of Engineering and Applied Sciences (SEAS), health, health services, Hedy Lamarr, Hedy's Folly, Huawei Canada, humanities, ICT, India, Information and Communication Technologies (ICT), Informing Research Choices: Indicators and Judgment (2012), Innovation and Business Strategy: Why Canada Falls Short (2009), inventor, Iran, James Somers, Japan, Justin Trudeau, Laura Barnett, Lisa Crossley, Lord of the Rings, Lucretius, Maastricht University, machine learning, Mark Twain, Marlon Brando, materials science, mathematics, Matthew Braga, McMaster University, medical informatics, Michelle N. Chretien, Microsoft, movie star, nanoscience and nanotechnology, Natalie Dakers, National Research Council Canada, Natural Philosophy, natural sciences, Naylor Report, Netherlands, OECD, On the Nature of the Universe, On the Nature of Things, open access, open data, open science, optoelectronics, Organization for Economic Cooperation and Development, other special machines, Paradox Lost: Explaining Canada's Research Strength and Innovation Weakness (2013), patents, Patrick D. Germain, performing arts, personalized medicine, Peter J. M. Nicholson, Peter Jackson, Pharmaceuticals, philosophy, photonics, physical sciences, physics, Pierre A. Mohnen, PISA scores, poetry, psychology, public health, R&D, Raymond G. Siemens, regenerative medicine, Reliq Health Technologies, research and development, Richard Rhodes, Robert Brian Haynes, Ronald Burnett, science technology engineering and mathematics, Sheridan College, social sciences, South Korea, start-up ecosystems, start-ups, statistics, Statistics Canada, STEM, Stephen Harper, Susan Holt, technometrics, telecommunications, The State of Industrial R&D in Canada (2013), The State of Science and Technology in Canada 2006, The State of Science and Technology in Canada 2012, theology, Third assessment of The State of Science and Technology and Industrial Research and Development in Canada, Third assessment on the State of S&T and IR&D, Turkey, UK, United Kingdom, United Nations University-MERIT, United States, University of Victoria, US, US Navy, visual, Wi-Fi, Wyss Institute, Ziegfeld Girl on April 12, 2018 by Maryse de la Giroday.
'Smart' fabric that's bony
Researchers at Australia's University of New South of Wales (UNSW) have devised a means of 'weaving' a material that mimics *bone tissue, periosteum according to a Jan. 11, 2017 news item on ScienceDaily,
For the first time, UNSW [University of New South Wales] biomedical engineers have woven a 'smart' fabric that mimics the sophisticated and complex properties of one nature's ingenious materials, the bone tissue periosteum.
Having achieved proof of concept, the researchers are now ready to produce fabric prototypes for a range of advanced functional materials that could transform the medical, safety and transport sectors. Patents for the innovation are pending in Australia, the United States and Europe.
Potential future applications range from protective suits that stiffen under high impact for skiers, racing-car drivers and astronauts, through to 'intelligent' compression bandages for deep-vein thrombosis that respond to the wearer's movement and safer steel-belt radial tyres.
A Jan. 11, 2017 UNSW press release on EurekAlert, which originated the news item, expands on the theme,
Many animal and plant tissues exhibit 'smart' and adaptive properties. One such material is the periosteum, a soft tissue sleeve that envelops most bony surfaces in the body. The complex arrangement of collagen, elastin and other structural proteins gives periosteum amazing resilience and provides bones with added strength under high impact loads.
Until now, a lack of scalable 'bottom-up' approaches by researchers has stymied their ability to use smart tissues to create advanced functional materials.
UNSW's Paul Trainor Chair of Biomedical Engineering, Professor Melissa Knothe Tate, said her team had for the first time mapped the complex tissue architectures of the periosteum, visualised them in 3D on a computer, scaled up the key components and produced prototypes using weaving loom technology.
"The result is a series of textile swatch prototypes that mimic periosteum's smart stress-strain properties. We have also demonstrated the feasibility of using this technique to test other fibres to produce a whole range of new textiles," Professor Knothe Tate said.
In order to understand the functional capacity of the periosteum, the team used an incredibly high fidelity imaging system to investigate and map its architecture.
"We then tested the feasibility of rendering periosteum's natural tissue weaves using computer-aided design software," Professor Knothe Tate said.
The computer modelling allowed the researchers to scale up nature's architectural patterns to weave periosteum-inspired, multidimensional fabrics using a state-of-the-art computer-controlled jacquard loom. The loom is known as the original rudimentary computer, first unveiled in 1801.
"The challenge with using collagen and elastin is their fibres, that are too small to fit into the loom. So we used elastic material that mimics elastin and silk that mimics collagen," Professor Knothe Tate said.
In a first test of the scaled-up tissue weaving concept, a series of textile swatch prototypes were woven, using specific combinations of collagen and elastin in a twill pattern designed to mirror periosteum's weave. Mechanical testing of the swatches showed they exhibited similar properties found in periosteum's natural collagen and elastin weave.
First author and biomedical engineering PhD candidate, Joanna Ng, said the technique had significant implications for the development of next-generation advanced materials and mechanically functional textiles.
While the materials produced by the jacquard loom have potential manufacturing applications – one tyremaker believes a titanium weave could spawn a new generation of thinner, stronger and safer steel-belt radials – the UNSW team is ultimately focused on the machine's human potential.
"Our longer term goal is to weave biological tissues – essentially human body parts – in the lab to replace and repair our failing joints that reflect the biology, architecture and mechanical properties of the periosteum," Ms Ng said.
An NHMRC development grant received in November [2016] will allow the team to take its research to the next phase. The researchers will work with the Cleveland Clinic and the University of Sydney's Professor Tony Weiss to develop and commercialise prototype bone implants for pre-clinical research, using the 'smart' technology, within three years.
In searching for more information about this work, I found a Winter 2015 article (PDF; pp. 8-11) by Amy Coopes and Steve Offner for UNSW Magazine about Knothe Tate and her work (Note: In Australia, winter would be what we in the Northern Hemisphere consider summer),
Tucked away in a small room in UNSW's Graduate School of Biomedical Engineering sits a 19th century–era weaver's wooden loom. Operated by punch cards and hooks, the machine was the first rudimentary computer when it was unveiled in 1801. While on the surface it looks like a standard Jacquard loom, it has been enhanced with motherboards integrated into each of the loom's five hook modules and connected to a computer. This state-of-the-art technology means complex algorithms control each of the 5,000 feed-in fibres with incredible precision.
That capacity means the loom can weave with an extraordinary variety of substances, from glass and titanium to rayon and silk, a development that has attracted industry attention around the world.
The interest lies in the natural advantage woven materials have over other manufactured substances. Instead of manipulating material to create new shades or hues as in traditional weaving, the fabrics' mechanical properties can be modulated, to be stiff at one end, for example, and more flexible at the other.
"Instead of a pattern of colours we get a pattern of mechanical properties," says Melissa Knothe Tate, UNSW's Paul Trainor Chair of Biomedical Engineering. "Think of a rope; it's uniquely good in tension and in bending. Weaving is naturally strong in that way."
The interface of mechanics and physiology is the focus of Knothe Tate's work. In March [2015], she travelled to the United States to present another aspect of her work at a meeting of the international Orthopedic Research Society in Las Vegas. That project – which has been dubbed "Google Maps for the body" – explores the interaction between cells and their environment in osteoporosis and other degenerative musculoskeletal conditions such as osteoarthritis.
Using previously top-secret semiconductor technology developed by optics giant Zeiss, and the same approach used by Google Maps to locate users with pinpoint accuracy, Knothe Tate and her team have created "zoomable" anatomical maps from the scale of a human joint down to a single cell.
She has also spearheaded a groundbreaking partnership that includes the Cleveland Clinic, and Brown and Stanford universities to help crunch terabytes of data gathered from human hip studies – all processed with the Google technology. Analysis that once took 25 years can now be done in a matter of weeks, bringing researchers ever closer to a set of laws that govern biological behaviour. [p. 9]
I gather she was recruited from the US to work at the University of New South Wales and this article was to highlight why they recruited her and to promote the university's biomedical engineering department, which she chairs.
Getting back to 2017, here's a link to and citation for the paper,
Scale-up of nature's tissue weaving algorithms to engineer advanced functional materials by Joanna L. Ng, Lillian E. Knothe, Renee M. Whan, Ulf Knothe & Melissa L. Knothe Tate. Scientific Reports 7, Article number: 40396 (2017) doi:10.1038/srep40396 Published online: 11 January 2017
One final comment, that's a lot of people (three out of five) with the last name Knothe in the author's list for the paper.
*'the bone tissue' changed to 'bone tissue' on July 17,2017.
This entry was posted in medicine and tagged advanced functional materials, Amy Coopes, Australia, bone, bottom-up engineering, Brown University, Cleveland Clinic, collagen, elastin, Europe, Google Maps, Google Maps for the body, jacquard loom, Joanna L. Ng, Joanna Ng, Lillian E. Knothe, mechanics, Melissa Knothe Tate, Melissa L. Knothe Tate, Orthopedic Research Society, patents, periosteum, Physiology, Renee M. Whan, Scale-up of nature's tissue weaving algorithms to engineer advanced functional materials, semiconductor technology, silk, smart fabric, Stanford University, Steve Offner, structural proteins, Tony Weiss, twill pattern, Ulf Knothe, University of New South Wales, University of Sydney, UNSW, US, weaving, Zeiss on January 20, 2017 by Maryse de la Giroday.
Are there any leaders in the 'graphene race'?
Tom Eldridge, a director and co-founder of Fullerex, has written a Jan. 5, 2017 essay titled: Is China still leading the graphene race? for Nanotechnology Now. Before getting to the essay, here's a bit more about Fullerex and Tom Eldridge's qualifications. From Fullerex's LinkedIn description,
Fullerex is a leading independent broker of nanomaterials and nano-intermediates. Our mission is to support the advancement of nanotechnology in creating radical, transformative and sustainable improvement to society. We are dedicated to achieving these aims by accelerating the commercialisation and usage of nanomaterials across industry and beyond. Fullerex is active in market development and physical trading of advanced materials. We generate demand for nanomaterials across synergistic markets by stimulating innovation with end-users and ensuring robust supply chains are in place to address the growing commercial trade interest. Our end-user markets include Polymers and Polymer Composites, Coatings, Tyre and Rubber, Cementitious Composites, 3D Printing and Printed Electronics, the Energy sector, Lubricating Oils and Functional Fluids. The materials we cover: Nanomaterials: Includes fullerenes, carbon nanotubes and graphene, metal and metal oxide nanoparticles, and organic-inorganic hybrids. Supplied as raw nanopowders or ready-to-use dispersions and concentrates. Nano-intermediates: Producer goods and semi-finished products such as nano-enabled coatings, polymer masterbatches, conductive inks, thermal interface materials and catalysts.
As for Tom Eldridge, here's more about him, his brother, and the company from the Fullerex About page,
Fullerex was founded by Joe and Tom Eldridge, brothers with a keen interest in nanotechnology and the associated emerging market for nanomaterials.
Joe has a strong background in trading with nearly 10 years' experience as a stockbroker, managing client accounts for European Equities and FX. At University he read Mathematics at Imperial College London gaining a BSc degree and has closely followed the markets for disruptive technologies and advanced materials for a number of years.
Tom worked in the City of London for 7 years in commercial roles throughout his professional career, with an expertise in market data, financial and regulatory news. In his academic background, he earned a BSc degree in Physics and Philosophy at Kings College London and is a member of the Institute of Physics.
As a result, Fullerex has the strong management composition that allows the company to support the growth of the nascent and highly promising nanomaterials industry. Fullerex is a flexible company with drive, enthusiasm and experience, committed to aiding the development of this market.
Getting back to the matter at hand, that's a rather provocative title for Tom Eldridge's essay,. given that he's a Brit and (I believe) the Brits viewed themselves as leaders in the 'graphene race' but he offers a more nuanced analysis than might be expected from the title. First, the patent landscape (from Eldridge's Jan. 5, 2017 essay),
As competition to exploit the "wonder material" has intensified around the world, detailed reports have so far been published which set out an in-depth depiction of the global patent landscape for graphene, notably from CambridgeIP and the UK Intellectual Property Office, in 2013 and 2015 respectively. Ostensibly the number of patents and patent applications both indicated that China was leading the innovation in graphene technology. However, on closer inspection it became less clear as to how closely the patent figures themselves reflect actual progress and whether this will translate into real economic impact. Some of the main reasons to be doubtful included:
– 98% of the Chinese patent applications only cover China, so therefore have no worldwide monopoly.
– A large number of the Chinese patents are filed in December, possibly due to demand to meet patent quotas. The implication being that the patent filings follow a politically driven agenda, rather than a purely innovation or commercially driven agenda.
– In general, inventors could be more likely to file for patent protection in some countries rather than others e.g. for tax purposes. Which therefore does not give a truly accurate picture of where all the actual research activity is based.
– Measuring the proportion of graphene related patents to overall patents is more indicative of graphene specialisation, which shows that Singapore has the largest proportion of graphene patents, followed by China, then South Korea.
(Intellectual Property Office, 2015), (Ellis, 2015), (CambridgeIP, 2013)
Then, there's the question of production,
Following the recent launch of the latest edition of the Bulk Graphene Pricing Report, which is available exclusively through The Graphene Council, Fullerex has updated its comprehensive list of graphene producers worldwide, and below is a summary of the number of graphene producers by country in 2017.
Summary Table Showing the Number of Graphene Producers by Country and Region
The total number of graphene producers identified is 142, across 27 countries. This research expands upon previous surveys of the graphene industry, such as the big data analysis performed by Nesta in 2015 (Shapira, 2015). The study by Nesta [formerly NESTA, National Endowment for Science, Technology and the Arts) is an independent charity that works to increase the innovation capacity of the UK; see Wikipedia here for more about NESTA] revealed 65 producers throughout 16 countries but was unable to glean accurate data on producers in Asia, particularly China.
As we can now see however from the data collected by Fullerex, China has the largest number of graphene producers, followed by the USA, and then the UK.
In addition to having more companies active in the production and sale of graphene than any other country, China also holds about 2/3rds of the global production capacity, according to Fullerex.
Eldridge goes on to note that the 'graphene industry' won't truly grow and develop until there are substantive applications for the material. He also suggests taking another look at the production figures,
As with the patent landscape, rather than looking at the absolute figures, we can review the numbers in relative terms. For instance, if we normalise to account for the differences in the size of each country, by looking at the number of producers as a proportion of GDP, we see the following: Spain (7.18), UK (4.48), India (3.73), China (3.57), Canada (3.28) [emphasis mine], USA (1.79) (United Nations, 2013).
Unsurprisingly, each leading country has a national strategy for economic development which involves graphene prominently.
For instance, The Spanish Council for Scientific Research has lent 9 of its institutes along with 10 universities and other public R&D labs involved in coordinating graphene projects with industry.
The Natural Sciences and Engineering Research Council of Canada [NSERC] has placed graphene as one of five research topics in its target area of "Advanced Manufacturing" for Strategic Partnership Grants.
The UK government highlights advanced materials as one of its Eight Great Technologies, within which graphene is a major part of, having received investment for the NGI and GEIC buildings, along with EPSRC and Innovate UK projects. I wrote previously about the UK punching above its weight in terms of research, ( http://fullerex.com/index.php/articles/130-the-uk-needs-an-industrial-revolution-can-graphene-deliver/ ) but that R&D spending relative to GDP was too low compared to other developed nations. It is good to see that investment into graphene production in the UK is bucking that trend, and we should anticipate this will provide a positive economic outcome.
Yes, I'm particularly interested in the fact Canada becomes more important as a producer when the numbers are relative but it is interesting to compare the chart with Eldridge's text and to note how importance shifts depending on what numbers are being considered.
I recommend reading Eldridge's piece in its entirety.
A few notes about graphene in Canada
By the way, the information in Eldridge's essay about NSERC's placement of graphene as a target area for grants is news to me. (As I have often noted here, I get more information about the Canadian nano scene from international sources than I do from our national sources.)
Happily I do get some home news such as a Jan. 5, 2017 email update from Lomiko Metals, a Canadian junior exploration company focused on graphite and lithium. The email provides the latest information from the company (as I'm not an expert in business or mining this is not an endorsement),
On December 13, 2016 we were excited to announce the completion of our drill program at the La Loutre flake graphite property. We received very positive results from our 1550 meter drilling program in 2015 in the area we are drilling now. In that release I stated, ""The intercepts of multiple zones of mineralization in the Refractory Zone where we have reported high grade intercepts previously is a very promising sign. The samples have been rushed to the ALS Laboratory for full assay testing," We hope to have the results of those assays shortly.
December 16, 2016 Lomiko announced a 10:1 roll back of our shares. We believe that this roll back is important as we work towards securing long term equity financing for the company. Lomiko began trading on the basis of the roll back on December 19.
We believe that Graphite has a bright future because of the many new products that will rely on the material. I have attached a link to a video on Lomiko, Graphite and Graphene.
https://youtu.be/Y–Y_Ub6oC4
January 3, 2017 Lomiko announced the extension and modification of its option agreements with Canadian Strategic Metals Inc. for the La Loutre and Lac des Iles properties. The effect of this extension is to give Lomiko additional time to complete the required work under the agreements.
Going forward Lomiko is in a much stronger position as the result of our share roll back. Potential equity funders who are very interested in our forthcoming assay results from La Loutre and the overall prospects of the company, have been reassured by our share consolidation.
Looking forward to 2017, we anticipate the assays of the La Loutre drilling to be delivered in the next 90 days, sooner we hope. We also anticipate additional equity funding will become available for the further exploration and delineation of the La Loutre and Lac des Iles properties and deposits.
More generally, we are confident that the market for large flake graphite will become firmer in 2017. Lomiko's strategy of identifying near surface, ready to mine, graphite nodes puts us in the position to take advantage of improvements in the graphite price without having to commit large sums to massive mine development. As we identify and analyze the graphite nodes we are finding we increase the potential resources of the company. 2017 should see significantly improved resource estimates for Lomiko's properties.
As I wasn't familiar with the term 'roll back of shares', I looked it up and found this in an April 18, 2012 posting by Dudley Pierce Baker on kitco.com,
As a general rule, we hate to see an announcement of a share rollback, however, there exceptions which we cover below. Investors should always be aware that if a company has, say over 150 million shares outstanding, in our opinion, it is a potential candidate for a rollback and the announcement should not come as a surprise.
Weak markets, a low share price, a large number of shares outstanding, little or no cash and you have a company which is an idea candidate for a rollback.
The basic concept of a rollback or consolidation in a company's shares is rather simple.
We are witnessing a few cases of rollbacks not with the purpose of raising more money but rather to facilitate the listing of the company's shares on the NYSE [New York Stock Exchange] Amex.
I have no idea what situation Lomiko finds itself in but it should be noted that graphere research has been active since 2004 when the first graphene sheets were extracted from graphite. This is a relatively new field of endeavour and Lomiko (along with other companies) is in the position of pioneering the effort here in Canada. That said, there are many competitors to graphene and major international race to commercialize nanotechnology-enabled products.
Getting back to the question in the headline, I don't think there are any leaders at the moment. No one seems to have what they used to call "a killer app," that one application/product that everyone wants and which drive demand for graphene.
This entry was posted in business, graphene, intellectual property, nanotechnology and tagged CambridgeIP, Canada, Canadian Strategic Metals, China, Dudley Pierce Baker, EPSRC, graphene producers, graphite, India, Innovate UK, Is China still leading the graphene race?, La Loutre, La Loutre Flake Graphite Property, La Loutre flake graphite property.Lomiko Metals, Lac Des Iles, large flake graphite, nano-intermediates. Joe Eldridge, nanomaterials, Natural Sciences and Engineering Research Council of Canada, NESTA, NESTA (National Endowment for Science Technology and the Arts), NSERC, Nw York Stock Exchange Annex, patents, share rollback, Singapore, South Korea, Spain, Spanish Council for Scientific Research, Tom Eldridge Fullerex, UK, UK Engineering and Physical Sciences Research Council, UK Intellectual Property Office, US on January 12, 2017 by Maryse de la Giroday.
Montreal Neuro creates a new paradigm for technology transfer?
It's one heck of a Christmas present. Canadian businessmen Larry Tannenbaum and his wife Judy have given the Montreal Neurological Institute (Montreal Neuro), which is affiliated with McGill University, a $20M donation. From a Dec. 16, 2016 McGill University news release,
The Prime Minister of Canada, Justin Trudeau, was present today at the Montreal Neurological Institute and Hospital (MNI) for the announcement of an important donation of $20 million by the Larry and Judy Tanenbaum family. This transformative gift will help to establish the Tanenbaum Open Science Institute, a bold initiative that will facilitate the sharing of neuroscience findings worldwide to accelerate the discovery of leading edge therapeutics to treat patients suffering from neurological diseases.
"Today, we take an important step forward in opening up new horizons in neuroscience research and discovery," said Mr. Larry Tanenbaum. "Our digital world provides for unprecedented opportunities to leverage advances in technology to the benefit of science. That is what we are celebrating here today: the transformation of research, the removal of barriers, the breaking of silos and, most of all, the courage of researchers to put patients and progress ahead of all other considerations."
Neuroscience has reached a new frontier, and advances in technology now allow scientists to better understand the brain and all its complexities in ways that were previously deemed impossible. The sharing of research findings amongst scientists is critical, not only due to the sheer scale of data involved, but also because diseases of the brain and the nervous system are amongst the most compelling unmet medical needs of our time.
Neurological diseases, mental illnesses, addictions, and brain and spinal cord injuries directly impact 1 in 3 Canadians, representing approximately 11 million people across the country.
"As internationally-recognized leaders in the field of brain research, we are uniquely placed to deliver on this ambitious initiative and reinforce our reputation as an institution that drives innovation, discovery and advanced patient care," said Dr. Guy Rouleau, Director of the Montreal Neurological Institute and Hospital and Chair of McGill University's Department of Neurology and Neurosurgery. "Part of the Tanenbaum family's donation will be used to incentivize other Canadian researchers and institutions to adopt an Open Science model, thus strengthening the network of like-minded institutes working in this field."
What they don't mention in the news release is that they will not be pursuing any patents (for five years according to one of the people in the video but I can't find text to substantiate that time limit*; there are no time limits noted elsewhere) on their work. For this detail and others, you have to listen to the video they've created,
The CBC (Canadian Broadcasting Corporation) news online Dec. 16, 2016 posting (with files from Sarah Leavitt and Justin Hayward) adds a few personal details about Tannenbaum,
"Our goal is simple: to accelerate brain research and discovery to relieve suffering," said Tanenbaum.
Tanenbaum, a Canadian businessman and chairman of Maple Leaf Sports and Entertainment, said many of his loved ones suffered from neurological disorders.
"I lost my mother to Alzheimer's, my father to a stroke, three dear friends to brain cancer, and a brilliant friend and scientist to clinical depression," said Tanenbaum.
He hopes the institute will serve as the template for science research across the world, a thought that Trudeau echoed.
"This vision around open science, recognizing the role that Canada can and should play, the leadership that Canadians can have in this initiative is truly, truly exciting," said Trudeau.
The Neurological Institute says the pharmaceutical industry is supportive of the open science concept because it will provide crucial base research that can later be used to develop drugs to fight an array of neurological conditions.
Jack Stilgoe in a Dec. 16, 2016 posting on the Guardian blogs explains what this donation could mean (Note: Links have been removed),
With the help of Tanenbaum's gift of 20 million Canadian dollars (£12million) the 'Neuro', the Montreal Neurological Institute and Hospital, is setting up an experiment in experimentation, an Open Science Initiative with the express purpose of finding out the best way to realise the potential of scientific research.
Governments in science-rich countries are increasingly concerned that they do not appear to reaping the economic returns they feel they deserve from investments in scientific research. Their favoured response has been to try to bridge what they see as a 'valley of death' between basic scientific research and industrial applications. This has meant more funding for 'translational research' and the flowering of technology transfer offices within universities.
… There are some success stories, particularly in the life sciences. Patents from the work of Richard Axel at Columbia University at one point brought the university almost $100 million per year. The University of Florida received more than $150 million for inventing Gatorade in the 1960s. The stakes are high in the current battle between Berkely and MIT/Harvard over who owns the rights to the CRISPR/Cas9 system that has revolutionised genetic engineering and could be worth billions.
Policymakers imagine a world in which universities pay for themselves just as a pharmaceutical research lab does. However, for critics of technology transfer, such stories blind us to the reality of university's entrepreneurial abilities.
For most universities, evidence of their money-making prowess is, to put it charitably, mixed. A recent Bloomberg report shows how quickly university patent incomes plunge once we look beyond the megastars. In 2014, just 15 US universities earned 70% of all patent royalties. British science policy researchers Paul Nightingale and Alex Coad conclude that 'Roughly 9/10 US universities lose money on their technology transfer offices… MIT makes more money from selling T-shirts than it does from licensing'. A report from the Brookings institute concluded that the model of technology transfer 'is unprofitable for most universities and sometimes even risks alienating the private sector'. In the UK, the situation is even worse. Businesses who have dealings with universities report that their technology transfer offices are often unrealistic in negotiations. In many cases, academics are, like a small child who refuses to let others play with a brand new football, unable to make the most of their gifts. And areas of science outside the life sciences are harder to patent than medicines, sports drinks and genetic engineering techniques. Trying too hard to force science towards the market may be, to use the phrase of science policy professor Keith Pavitt, like pushing a piece of string.
Science policy is slowly waking up to the realisation that the value of science may lie in people and places rather than papers and patents. It's an idea that the Neuro, with the help of Tanenbaum's gift, is going to test. By sharing data and giving away intellectual property, the initiative aims to attract new private partners to the institute and build Montreal as a hub for knowledge and innovation. The hypothesis is that this will be more lucrative than hoarding patents.
This experiment is not wishful thinking. It will be scientifically measured. It is the job of Richard Gold, a McGill University law professor, to see whether it works. He told me that his first task is 'to figure out what to counts… There's going to be a gap between what we would like to measure and what we can measure'. However, he sees an open-mindedness among his colleagues that is unusual. Some are evangelists for open science; some are sceptics. But they share a curiosity about new approaches and a recognition of a problem in neuroscience: 'We haven't come up with a new drug for Parkinson's in 30 years. We don't even understand the biological basis for many of these diseases. So whatever we're doing at the moment doesn't work'. …
Montreal Neuro made news on the 'open science' front in January 2016 when it formally announced its research would be freely available and that researchers would not be pursuing patents (see my January 22, 2016 posting).
I recommend reading Stilgoe's posting in its entirety and for those who don't know or have forgotten, Prime Minister's Trudeau's family has some experience with mental illness. His mother has been very open about her travails. This makes his presence at the announcement perhaps a bit more meaningful than the usual political presence at a major funding announcement.
*The five-year time limit is confirmed in a Feb. 17, 2017 McGill University news release about their presentations at the AAAS (American Association for the Advancement of Science) 2017 annual meeting) on EurekAlert,
umpstarting Neurological Research through Open Science – MNI & McGill University
Friday, February 17, 2017, 1:30-2:30 PM/ Room 208
Neurological research is advancing too slowly according to Dr. Guy Rouleau, director of the Montreal Neurological Institute (MNI) of McGill University. To speed up discovery, MNI has become the first ever Open Science academic institution in the world. In a five-year experiment, MNI is opening its books and making itself transparent to an international group of social scientists, policymakers, industrial partners, and members of civil society. They hope, by doing so, to accelerate research and the discovery of new treatments for patients with neurological diseases, and to encourage other leading institutions around the world to consider a similar model. A team led by McGill Faculty of Law's Professor Richard Gold will monitor and evaluate how well the MNI Open Science experiment works and provide the scientific and policy worlds with insight into 21st century university-industry partnerships. At this workshop, Rouleau and Gold will discuss the benefits and challenges of this open-science initiative.
This entry was posted in intellectual property, science and tagged addictions, Alex Coad, brain injuries, Columbia University, CRISPR/Cas9 system, Gatorade, Guy Rouleau, Harvard University, Jack Stilgoe, Judy Tannenbaum, Justin Hayward, Justin Trudeau, Keith Pavitt, Larry Tannenbaum, Massachusetts Institute of Technology, McGill University, mental illnesses, MIT, Montréal Neuro, Montreal Neurological Institute, neurological diseases, open science, patents, Paul Nightingale, Richard Axel, Sarah Leavitt, spinal cord injuries, Tanenbaum Open Science Institute, University of Florida on December 19, 2016 by Maryse de la Giroday.
Exceeding the sensitivity of skin with a graphene elastomer
A Jan. 14, 2016 news item on Nanowerk announces the latest in 'sensitive' skin,
A new sponge-like material, discovered by Monash [Monash University in Australia] researchers, could have diverse and valuable real-life applications. The new elastomer could be used to create soft, tactile robots to help care for elderly people, perform remote surgical procedures or build highly sensitive prosthetic hands.
Graphene-based cellular elastomer, or G-elastomer, is highly sensitive to pressure and vibrations. Unlike other viscoelastic substances such as polyurethane foam or rubber, G-elastomer bounces back extremely quickly under pressure, despite its exceptionally soft nature. This unique, dynamic response has never been found in existing soft materials, and has excited and intrigued researchers Professor Dan Li and Dr Ling Qiu from the Monash Centre for Atomically Thin Materials (MCATM).
A Jan. 14, 2016 Monash University media release, which originated the news item, offers some insights from the researchers,
According to Dr Qiu, "This graphene elastomer is a flexible, ultra-light material which can detect pressures and vibrations across a broad bandwidth of frequencies. It far exceeds the response range of our skin, and it also has a very fast response time, much faster than conventional polymer elastomer.
"Although we often take it for granted, the pressure sensors in our skin allow us to do things like hold a cup without dropping it, crushing it, or spilling the contents. The sensitivity and response time of G-elastomer could allow a prosthetic hand or a robot to be even more dexterous than a human, while the flexibility could allow us to create next generation flexible electronic devices," he said.
Professor Li, a director of MCATM, said, 'Although we are still in the early stages of discovering graphene's potential, this research is an excellent breakthrough. What we do know is that graphene could have a huge impact on Australia's economy, both from a resources and innovation perspective, and we're aiming to be at the forefront of that research and development.'
Dr Qiu's research has been published in the latest edition of the prestigious journal Advanced Materials and is protected by a suite of patents.
Are they trying to protect the work from competition or wholesale theft of their work?
After all, the idea behind patents and copyrights was to encourage innovation and competition by ensuring that inventors and creators would benefit from their work. An example that comes to mind is the Xerox company which for many years had a monopoly on photocopy machines by virtue of their patent. Once the patent ran out (patents and copyrights were originally intended to be in place for finite time periods) and Xerox had made much, much money, competitors were free to create and market their own photocopy machines, which they did quite promptly. Since those days, companies have worked to extend patent and copyright time periods in efforts to stifle competition.
Getting back to Monash, I do hope the researchers are able to benefit from their work and wish them well. I also hope that they enjoy plenty of healthy competition spurring them onto greater innovation.
Here's a link to and a citation for their paper,
Ultrafast Dynamic Piezoresistive Response of Graphene-Based Cellular Elastomers by Ling Qiu, M. Bulut Coskun, Yue Tang, Jefferson Z. Liu, Tuncay Alan, Jie Ding, Van-Tan Truong, and Dan Li. Advanced Materials Volume 28, Issue 1 January 6, 2016Pages 194–200 DOI: 10.1002/adma.201503957 First published: 2 November 2015
This entry was posted in graphene, nanotechnology, robots and tagged Australia, copyright, Dan Li, elastomer, graphene-based cellular elastomer, Jefferson Z. Liu, Jie Ding, Ling Qiu, M. Bulut Coskun, Monash University, or G-elastomer, patents, sponge-like material, Tuncay Alan, Ultrafast Dynamic Piezoresistive Response of Graphene-Based Cellular Elastomers, Van-Tan Truong, Yue Tang on January 14, 2016 by Maryse de la Giroday.
Copyright and patent protections and human rights
The United Nations (UN) and cultural rights don't immediately leap to mind when the subjects of copyright and patents are discussed. A Mar. 13, 2015 posting by Tim Cushing on Techdirt and an Oct. 14, 2015 posting by Glyn Moody also on Techdirt explain the connection in the person of Farida Shaheed, the UN Special Rapporteur on cultural rights and the author of two UN reports one on copyright and one on patents.
From the Mar. 13, 2015 posting by Tim Cushing,
… Farida Shaheed, has just delivered a less-than-complimentary report on copyright to the UN's Human Rights Council. Shaheed's report actually examines where copyright meshes with arts and science — the two areas it's supposed to support — and finds it runs contrary to the rosy image of incentivized creation perpetuated by the MPAAs and RIAAs of the world.
Shaheed said a "widely shared concern stems from the tendency for copyright protection to be strengthened with little consideration to human rights issues." This is illustrated by trade negotiations conducted in secrecy, and with the participation of corporate entities, she said.
She stressed the fact that one of the key points of her report is that intellectual property rights are not human rights. "This equation is false and misleading," she said.
The last statement fires shots over the bows of "moral rights" purveyors, as well as those who view infringement as a moral issue, rather than just a legal one.
Shaheed also points out that the protections being installed around the world at the behest of incumbent industries are not necessarily reflective of creators' desires. …
Glyn Moody's Oct. 14, 2015 posting features Shaheed's latest report on patents,
… As the summary to her report puts it:
There is no human right to patent protection. The right to protection of moral and material interests cannot be used to defend patent laws that inadequately respect the right to participate in cultural life, to enjoy the benefits of scientific progress and its applications, to scientific freedoms and the right to food and health and the rights of indigenous peoples and local communities.
Patents, when properly structured, may expand the options and well-being of all people by making new possibilities available. Yet, they also give patent-holders the power to deny access to others, thereby limiting or denying the public's right of participation to science and culture. The human rights perspective demands that patents do not extend so far as to interfere with individuals' dignity and well-being. Where patent rights and human rights are in conflict, human rights must prevail.
The report touches on many issues previously discussed here on Techdirt. For example, how pharmaceutical patents limit access to medicines by those unable to afford the high prices monopolies allow — a particularly hot topic in the light of TPP's rules on data exclusivity for biologics. The impact of patents on seed independence is considered, and there is a warning about corporate sovereignty chapters in trade agreements, and the chilling effects they can have on the regulatory function of states and their ability to legislate in the public interest — for example, with patent laws.
I have two Canadian examples for data exclusivity and corporate sovereignty issues, both from Techdirt. There's an Oct. 19, 2015 posting by Glyn Moody featuring a recent Health Canada move to threaten a researcher into suppressing information from human clinical trials,
… one of the final sticking points of the TPP negotiations [Trans Pacific Partnership] was the issue of data exclusivity for the class of drugs known as biologics. We've pointed out that the very idea of giving any monopoly on what amounts to facts is fundamentally anti-science, but that's a rather abstract way of looking at it. A recent case in Canada makes plain what data exclusivity means in practice. As reported by CBC [Canadian Broadcasting Corporation] News, it concerns unpublished clinical trial data about a popular morning sickness drug:
Dr. Navindra Persaud has been fighting for four years to get access to thousands of pages of drug industry documents being held by Health Canada.
He finally received the material a few weeks ago, but now he's being prevented from revealing what he has discovered.
That's because Health Canada required him to sign a confidentiality agreement, and has threatened him with legal action if he breaks it.
The clinical trials data is so secret that he's been told that he must destroy the documents once he's read them, and notify Health Canada in writing that he has done so….
For those who aren't familiar with it, the Trans Pacific Partnership is a proposed trade agreement including 12 countries (Australia, Brunei Darussalam, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, United States, and Vietnam) from the Pacific Rim. If all the countries sign on (it looks as if they will; Canada's new Prime Minister as of Oct. 19, 2015 seems to be in favour of the agreement although he has yet to make a definitive statement), the TPP will represent a trading block that is almost double the size of the European Union.
An Oct. 8, 2015 posting by Mike Masnick provides a description of corporate sovereignty and of the Eli Lilly suit against the Canadian government.
We've pointed out a few times in the past that while everyone refers to the Trans Pacific Partnership (TPP) agreement as a "free trade" agreement, the reality is that there's very little in there that's actually about free trade. If it were truly a free trade agreement, then there would be plenty of reasons to support it. But the details show it's not, and yet, time and time again, we see people supporting the TPP because "well, free trade is good." …
… it's that "harmonizing regulatory regimes" thing where the real nastiness lies, and where you quickly discover that most of the key factors in the TPP are not at all about free trade, but the opposite. It's about as protectionist as can be. That's mainly because of the really nasty corprorate sovereignty clauses in the agreement (which are officially called "investor state dispute settlement" or ISDS in an attempt to make it sound so boring you'll stop paying attention). Those clauses basically allow large incumbents to force the laws of countries to change to their will. Companies who feel that some country's regulation somehow takes away "expected profits" can convene a tribunal, and force a country to change its laws. Yes, technically a tribunal can only issue monetary sanctions against a country, but countries who wish to avoid such monetary payments will change their laws.
Remember how Eli Lilly is demanding $500 million from Canada after Canada rejected some Eli Lilly patents, noting that the new compound didn't actually do anything new and useful? Eli Lilly claims that using such a standard to reject patents unfairly attacks its expected future profits, and thus it can demand $500 million from Canadian taxpayers. Now, imagine that on all sorts of other systems.
Cultural rights, human rights, corporate rights. It would seem that corporate rights are going to run counter to human rights, if nothing else.
This entry was posted in copyright, economics, intellectual property, science policy and tagged Australia, biologics, Brunei Darussalam, Canada, Chile, copyright, corporate sovereignty, data exclusivity, Eli Lilly, Glyn Moody, investor state dispute settlement (ISDS), ISDS, Japan, Malaysia, Mexico, Mike Masnick, New Zealand, patents, Peru, Singapore, Tim Cushing, TPP, Trans Pacific Partnership (TPP), United States, Vietnam on October 22, 2015 by Maryse de la Giroday.
Is it time to invest in a 'brain chip' company?
This story take a few twists and turns. First, 'brain chips' as they're sometimes called would allow, theoretically, computers to learn and function like human brains. (Note: There's another type of 'brain chip' which could be implanted in human brains to help deal with diseases such as Parkinson's and Alzheimer's. *Today's [June 26, 2015] earlier posting about an artificial neuron points at some of the work being done in this areas.*)
Returning to the 'brain ship' at hand. Second, there's a company called BrainChip, which has one patent and another pending for, yes, a 'brain chip'.
The company, BrainChip, founded in Australia and now headquartered in California's Silicon Valley, recently sparked some investor interest in Australia. From an April 7, 2015 article by Timna Jacks for the Australian Financial Review,
Former mining stock Aziana Limited has whet Australian investors' appetite for science fiction, with its share price jumping 125 per cent since it announced it was acquiring a US-based tech company called BrainChip, which promises artificial intelligence through a microchip that replicates the neural system of the human brain.
Shares in the company closed at 9¢ before the Easter long weekend, having been priced at just 4¢ when the backdoor listing of BrainChip was announced to the market on March 18.
Creator of the patented digital chip, Peter Van Der Made told The Australian Financial Review the technology has the capacity to learn autonomously, due to its composition of 10,000 biomimic neurons, which, through a process known as synaptic time-dependent plasticity, can form memories and associations in the same way as a biological brain. He said it works 5000 times faster and uses a thousandth of the power of the fastest computers available today.
Mr Van Der Made is inviting technology partners to license the technology for their own chips and products, and is donating the technology to university laboratories in the US for research.
The Netherlands-born Australian, now based in southern California, was inspired to create the brain-like chip in 2004, after working at the IBM Internet Security Systems for two years, where he was chief scientist for behaviour analysis security systems. …
A June 23, 2015 article by Tony Malkovic on phys.org provide a few more details about BrainChip and about the deal,
Mr Van der Made and the company, also called BrainChip, are now based in Silicon Valley in California and he returned to Perth last month as part of the company's recent merger and listing on the Australian Stock Exchange.
He says BrainChip has the ability to learn autonomously, evolve and associate information and respond to stimuli like a brain.
Mr Van der Made says the company's chip technology is more than 5,000 faster than other technologies, yet uses only 1/1,000th of the power.
"It's a hardware only solution, there is no software to slow things down," he says.
"It doesn't executes instructions, it learns and supplies what it has learnt to new information.
"BrainChip is on the road to position itself at the forefront of artificial intelligence," he says.
"We have a clear advantage, at least 10 years, over anybody else in the market, that includes IBM."
BrainChip is aiming at the global semiconductor market involving almost anything that involves a microprocessor.
You can find out more about the company, BrainChip here. The site does have a little more information about the technology,
Spiking Neuron Adaptive Processor (SNAP)
BrainChip's inventor, Peter van der Made, has created an exciting new Spiking Neural Networking technology that has the ability to learn autonomously, evolve and associate information just like the human brain. The technology is developed as a digital design containing a configurable "sea of biomimic neurons'.
The technology is fast, completely digital, and consumes very low power, making it feasible to integrate large networks into portable battery-operated products, something that has never been possible before.
BrainChip neurons autonomously learn through a process known as STDP (Synaptic Time Dependent Plasticity). BrainChip's fully digital neurons process input spikes directly in hardware. Sensory neurons convert physical stimuli into spikes. Learning occurs when the input is intense, or repeating through feedback and this is directly correlated to the way the brain learns.
Computing Artificial Neural Networks (ANNs)
The brain consists of specialized nerve cells that communicate with one another. Each such nerve cell is called a Neuron,. The inputs are memory nodes called synapses. When the neuron associates information, it produces a 'spike' or a 'spike train'. Each spike is a pulse that triggers a value in the next synapse. Synapses store values, similar to the way a computer stores numbers. In combination, these values determine the function of the neural network. Synapses acquire values through learning.
In Artificial Neural Networks (ANNs) this complex function is generally simplified to a static summation and compare function, which severely limits computational power. BrainChip has redefined how neural networks work, replicating the behaviour of the brain. BrainChip's artificial neurons are completely digital, biologically realistic resulting in increased computational power, high speed and extremely low power consumption.
The Problem with Artificial Neural Networks
Standard ANNs, running on computer hardware are processed sequentially; the processor runs a program that defines the neural network. This consumes considerable time and because these neurons are processed sequentially, all this delayed time adds up resulting in a significant linear decline in network performance with size.
BrainChip neurons are all mapped in parallel. Therefore the performance of the network is not dependent on the size of the network providing a clear speed advantage. So because there is no decline in performance with network size, learning also takes place in parallel within each synapse, making STDP learning very fast.
A hardware solution
BrainChip's digital neural technology is the only custom hardware solution that is capable of STDP learning. The hardware requires no coding and has no software as it evolves learning through experience and user direction.
The BrainChip neuron is unique in that it is completely digital, behaves asynchronously like an analog neuron, and has a higher level of biological realism. It is more sophisticated than software neural models and is many orders of magnitude faster. The BrainChip neuron consists entirely of binary logic gates with no traditional CPU core. Hence, there are no 'programming' steps. Learning and training takes the place of programming and coding. Like of a child learning a task for the first time.
Software 'neurons', to compromise for limited processing power, are simplified to a point where they do not resemble any of the features of a biological neuron. This is due to the sequential nature of computers, whereby all data has to pass through a central processor in chunks of 16, 32 or 64 bits. In contrast, the brain's network is parallel and processes the equivalent of millions of data bits simultaneously.
A significantly faster technology
Performing emulation in digital hardware has distinct advantages over software. As software is processed sequentially, one instruction at a time, Software Neural Networks perform slower with increasing size. Parallel hardware does not have this problem and maintains the same speed no matter how large the network is. Another advantage of hardware is that it is more power efficient by several orders of magnitude.
The speed of the BrainChip device is unparalleled in the industry.
For large neural networks a GPU (Graphics Processing Unit) is ~70 times faster than the Intel i7 executing a similar size neural network. The BrainChip neural network is faster still and takes far fewer CPU (Central Processing Unit) cycles, with just a little communication overhead, which means that the CPU is available for other tasks. The BrainChip network also responds much faster than a software network accelerating the performance of the entire system.
The BrainChip network is completely parallel, with no sequential dependencies. This means that the network does not slow down with increasing size.
Endorsed by the neuroscience community
A number of the world's pre-eminent neuroscientists have endorsed the technology and are agreeing to joint develop projects.
BrainChip has the potential to become the de facto standard for all autonomous learning technology and computer products.
BrainChip's autonomous learning technology patent was granted on the 21st September 2008 (Patent number US 8,250,011 "Autonomous learning dynamic artificial neural computing device and brain inspired system"). BrainChip is the only company in the world to have achieved autonomous learning in a network of Digital Neurons without any software.
A prototype Spiking Neuron Adaptive Processor was designed as a 'proof of concept' chip.
The first tests were completed at the end of 2007 and this design was used as the foundation for the US patent application which was filed in 2008. BrainChip has also applied for a continuation-in-part patent filed in 2012, the "Method and System for creating Dynamic Neural Function Libraries", US Patent Application 13/461,800 which is pending.
Van der Made doesn't seem to have published any papers on this work and the description of the technology provided on the website is frustratingly vague. There are many acronyms for processes but no mention of what this hardware might be. For example, is it based on a memristor or some kind of atomic ionic switch or something else altogether?
It would be interesting to find out more but, presumably, van der Made, wishes to withhold details. There are many companies following the same strategy while pursuing what they view as a business advantage.
* Artificial neuron link added June 26, 2015 at 1017 hours PST.
This entry was posted in human enhancement, intellectual property and tagged artificial brain, Artificial Neural Networks (ANNs), Australia, BrainChip, California, Computing Artificial Neural Networks (ANNs), Delaware, neuromorphic computing, neuromorphic engineering, neurons, patents, Peter Van Der Made, Spiking Neural Networking technology, Spiking Neuron Adaptive Processor (SNAP), STDP (Synaptic Time Dependent Plasticity), synapses, Timna Jacks, Tony Malkovic Aziana Limited on June 26, 2015 by Maryse de la Giroday.